Occurrence of infections with multiple human papillomavirus (HPV) types among Finnish and Ugandan women by Namujju, Proscovia Bazanya
80
O
ccurrence of infections w
ith m
ultiple hum
an papillom
avirus (H
PV) types 
am
ong Finnish and U
gandan w
om
en
80
2012
Proscovia Bazanya N
am
ujju
Proscovia Bazanya Namujju
Occurrence of infections with multiple 
human papillomavirus (HPV) types 
among Finnish and Ugandan women
80
Oncogenic human papillomavirus (HPV) types are necessary cause of cervical cancer 
(CC), the third leading cancer among women worldwide.
We studied the distribution and the risk of HPV type occurrence among Finnish and 
Uganda women using type-specific antibodies as markers of exposure to HPVs.
Our results indicate that seroprevalences to any HPV type and multiple types were 
common in both female groups but higher among Ugandans. The risk of being 
seropositive for another given HPV type was increased among women seropositive 
for a specific HPV type compared to seronegative women for that particular type. 
The risk of double seropositivity for HPV18, 31, 33 was significantly higher among 
HPV45 seropositive Finns than Ugandans. Among Ugandan women, HIV was the 
only stand-alone risk factor for seropositivity for multiple HPV type, however, the 
risk of double seropositivity for particular HPV types was not significantly different 
among HIV positive and HIV negative women. We also noted that Ugandan women 
with low avidity HPV16 antibodies had a significantly increased risk of being 
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highest burden of CC and endemic HIV, proof of vaccine efficacy against multiple 
HPVs is urgently needed.
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Abstract 
Proscovia Bazanya Namujju. Occurrence of infections with multiple human papil-
lomavirus (HPV) types among Finnish and Ugandan women. National Institute for 
Health and Welfare (THL). Research 80. 141 pages. Helsinki, Finland 2012. 
ISBN 978-952-245-644-1 (printed); ISBN 978-952-245-645-8 (pdf) 
 
Cervical cancer (CC) is a major public health problem in women, especially in Sub-
Saharan Africa. The prevalence of oncogenic, high-risk (hr) human papillomavi-
ruses (hrHPVs), the sexually transmitted, necessary causative agents of CC, is on the 
increase due to increasing risk-taking sexual behaviour among the young. Despite 
the transient nature of HPV infection, infections of hrHPV types are associated with 
viral persistence and increased risk for cervical intraepithelial neoplasia (CIN) de-
velopment. The reported overall efficacy of licenced, prophylactic HPV vaccines 
against CIN grade 3 is between 93 and 100% in developed countries. However, it is 
necessary to understand the distribution of genital (both low risk, lr and hr) HPV 
types, and factors that may interfere with the immunogenicity and efficacy of the 
prophylactic HPV vaccines in Sub-Saharan countries before mass HPV vaccination 
is implemented. 
 
In this dissertation we use serum antibodies, a stable marker of cumulative (past and 
present) HPV exposure to study the occurrence of anogenital HPV infections and 
associated risk factors among fertile-aged Finnish and Ugandan women.  
 
A cross-sectional study was conducted among Finnish pregnant women who do-
nated blood samples to the Finnish Maternity Cohort (FMC) from 1995 to 2003 
(Papers I and IV). Ugandan pregnant women were recruited in two phases in 2004 
and again in 2008 (Papers I, II and IV). In a prospective study (Paper III) we used 
serum samples collected at baseline and at the end of the follow-up of the women 
from the Finnish Kuopio cohort. The samples were analysed for antibodies against 7 
HPV types (6/11/16/18/31/33/45) using standard VLP-based ELISAs (Papers I, III) 
and a modified VLP-based ELISA (Paper IV), and using Multiplex serology for 
antibodies against 8 oncogenic HPV types (16/18/31/33/35/45/52/58) (Paper II). 
Other standard laboratory measurements were serum cotinine (smoking), HIV and 
Chlamydia trachomatis antibodies tests. In addition, questionnaire data for risk fac-
tors for acquiring genital HPV infections were available for the Ugandan women. 
 
We found that seropositivity to multiple HPV types was highly prevalent in both 
Finnish (any type=44%, multiple types =22%) and Ugandan women (any type 57%, 
multiple types 33%). In both groups the prevalence of HPV was highest among the 
young women under 25 years of age. It was higher among Ugandan than Finnish 
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women. The most common virus types (in descending order) were: HPV16, 18, 31 
and 33 (Finland) and HPV33, 16, 31, 45 (Uganda).  
 
The risk of being seropositive for another given HPV type was significantly in-
creased among women seropositive for a specific HPV type compared to seronega-
tive women for that particular type (Paper I). Among HPV45- seropositive Finnish 
women the risk of double seropositivity for HPV18, 31, and 33 was significantly 
higher than among Ugandan women (Paper I). We also observed that age, education, 
parity and HIV were risk factors for hrHPV seropositivity, but HIV was the only 
independent, stand-alone risk factor of seropositivity for multiple hrHPV types 
among Ugandan women (OR 1.7, 95%CI 1.0-2.8) (Paper II).  
 
In the prospective study, baseline HPV16 seropositive women had a significantly 
increased risk of seroconversion to phylogenetically related HPV types 31 and 33 
compared to seronegative women. On the other hand, seropositivity for lrHPV types 
increased the risk of seroconversion to hrHPV types (OR 2.3, 95%CI 1.1-4.7) (Paper 
III). Moreover, we observed that low avidity HPV16 antibodies (suggesting acute 
infections or persistent low avidity) were common (18%) and associated with the 
risk of being seropositive for lrHPV types among Ugandan women (OR 2.2, 95%CI 
1.01-8.4) (Paper IV). 
 
Sizeable study cohorts allowed thorough comparison of variables. The pregnant 
women studied represent the majority of sexually active young/fertile-aged women. 
Type-specificity of the antibody tests and stability of the HPV antibodies allowed 
analysis of cumulative HPV infections during a period of more than five years. 
There were, however, also limitations in our studies; the cross-sectional nature of the 
two studies did not allow us to assess the order of acquisition of HPV infection, and 
in the prospective study the exact acquisition time could not be determined. We also 
lacked HPV DNA data and CD4 counts to distinguish current HPV infections from 
past infections, and to assess the immunological status of the HIV-positive study 
subjects, respectively.  
 
Our results indicate that the risk of acquiring multiple HPVs is high among women 
exposed to any HPV type, but especially among women already infected with 
HPV16 and HPV18. Viral clearance in individuals with multiple HPV infections is 
exclusively determined by the HIV status. Therefore prophylactic mass HPV vacci-
nation will be crucial in the control of the hrHPV types and associated disease bur-
den in the young women of countries like Uganda, where HIV is endemic. Data on 
HPV vaccine efficacy and its determinants in Sub-Saharan Africa is urgently needed.  
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Tiivistelmä 
Proscovia Bazanya Namujju. Useiden ihmisen papilloomavirustyyppien aiheuttamat 
infektiot suomalaisilla ja ugandalaisilla naisilla. Terveyden ja Hyvinvoinnin laitos 
(THL). Tutkimus 80. 141 sivua. Helsinki, Suomi 2012. 
ISBN 978-952-245-644-1 (printed); ISBN 978-952-245-645-8 (pdf) 
 
Kohdunkaulansyöpä on suuri naisten kansanterveydellinen ongelma, erityisesti Sa-
haran alapuolisessa Afrikassa. Syöpävaarallisten, korkean riskin (hr), ihmisen papil-
loomavirus (HPV) tyyppien, jotka ovat kohdunkaulansyövän syy, esiintyminen on 
nousussa nuorten kasvaneen seksuaalisen riskikäyttäytymisen vuoksi. Ohimenevästä 
luonteestaan huolimatta, hrHPV infektioihin voi liittyä pitkittymistä ja lisääntynyt 
riski kehittää kohdunkaulansyövän esiaste (CIN). Lisensoitujen, ennaltaehkäisevien 
rokotteiden raportoitu kokonaisteho CIN luokka 3 muutosta vastaan on kehittyneissä 
maissa 93 ja 100% välillä. On kuitenkin välttämätöntä tuntea genitaali-infektioita 
aiheuttavien HPV tyyppien (sekä matalan riskin, lr että hr tyypit), ja tekijöiden, jotka 
voivat häiritä ennaltaehkäisevien rokotteiden immunogeenisuutta ja tehoa, esiinty-
vyys ennen kuin HPV joukkorokotukset Saharan alapuolisessa Afrikassa pannaan 
toimeen.  
 
Tässä väitöskirjatyössä käytimme seerumin vasta-aineita, stabiilia kumulatiivisten 
(aikaisempien ja nykyisten) HPV altistusten markkeria tutkittaessa anogenitaalisten 
HPV infektioiden esiintymistä ja niihin liittyviä riskitekijöitä fertiili-ikäisillä suoma-
laisilla ja ugandalaisilla naisilla. 
 
Teimme poikkileikkaustutkimuksen suomalaisilla raskaana olevilla naisilla, jotka 
olivat antaneet verinäytteen Finnish Maternity Cohort (FMC) aitiysneuvolaseerumi-
pankkiin 1995 - 2003 (Työt I ja IV). Ugandalaiset raskaana olleet naiset rekrytoitiin 
kahdessa vaiheessa 2004 ja 2008 (Työt I, II ja IV). Prospektiivisessa tutkimuksessa 
(Työ III) käytimme seeruminäytteitä, jotka oli kerätty seurannan alku- ja päätösvai-
heessa naisilta, jotka kuuluivat suomalaiseen Kuopio kohorttiin. Näytteet analysoi-
tiin 7 HPV tyypin (6/11/16/18/31/33/45) vasta-aineiden suhteen käyttäen standardi 
VLP-pohjoista ELISA menetelmää (Työt I, III) ja muunneltua VLP-pohjoista ELI-
SAa (Paper IV), ja Multiplex serologiaa kahdeksan syöpävaarallisen HPV tyypin 
(16/18/31/33/35/45/52/58) vasta-aineiden mittaamiseen (Työ II). Muita standardi 
laboratoriomittauksia olivat seerumin cotiniini (tupakointi), HIV and Chlamydia 
trachomatis vasta-ainetestit. Lisäksi, ugandalaisilta naisilta oli käytössä kyselytietoa 
genitaali HPV-infektioiden saannin riskitekijöistä. 
 
Havaitsimme, että seropositiivisuus useilla HPV tyypeille oli hyvin yleistä sekä 
suomalaisilla (mikä tahansa HPV tyyppi=44%, useampi tyyppi=22%) että uganda-
laisilla naisilla (mikä tahansa HPV tyyppi=57%, useampi tyyppi=33%). Molemmis-
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sa ryhmissä HPV esiintyvyys oli korkein nuorilla, alle 25 -vuotiailla. Esiintyvyys oli 
korkeampaa ugandalaisilla kuin suomalaisilla naisilla. Yleisimmät HPV tyypit olivat 
(alenevassa järjestyksessä): HPV16, 18, 31 ja 33 (Suomi) ja HPV33, 16, 31, 45 
(Uganda).  
 
Riski olla seropositiivinen tietylle HPV tyypille oli kohonnut niiden naisten joukossa, 
jotka olivat seropositiivisia jonkin toisen, spesifisen HPV tyypin suhteen verrattuna 
tämän HPV tyypin suhteen seronegatiivisiin naisiin (Työ I). HPV45 seropositiivisil-
la suomalaisnaisilla riski olla tupla- seropositiivisia sen ja HPV tyyppien 18, 31, ja 
33 suhteen oli merkitsevästi korkeampi kuin ugandalaisnaisilla (Työ I). Havaitsim-
me myös, että ikä, koulutus, pariteetti ja HIV olivat hrHPV seropositiivisuuden ris-
kitekijöitä, mutta että HIV oli ainoa itsenäinen useamman hrHPV tyypin seropositii-
visyyden riskitekijä ugandalaisnaisilla (OR 1.7, 95%CI 1.0-2.8) (Työ II).  
 
Prospektiivisessa työssä alkuhetkellä HPV16 seropositiivisilla naisilla oli merkitse-
västi kohonnut riski serokonvertoida fylogeneettisesti sukulais-HPV tyyppien 31 ja 
33 suhteen verrattuna seronegatiivisiin naisiin. Toisaalta seropositiivisuus lrHPV 
tyyppien suhteen lisäsi riskiä serokonvertoida hrHPV tyyppien suhteen (OR 2.3, 
95%CI 1.1-4.7) (Työ III). Lisäksi havaitsimme, että ugandalaisnaisilla matalan avi-
diteetin HPV16 vasta-aineet (mahdollisesti merkkinä akuutista infektiosta tai pitkit-
tyneestä matalasta aviditeetista) olivat yleisiä (18%) ja liittyivät riskiin omata vasta-
aineita lrHPV tyypeille (OR 2.2, 95%CI 1.01-8.4) (Työ IV). 
 
Kookkaat tutkimuskohortit mahdollistivat muuttujien perinpohjaisen vertailun. Ras-
kaana olevat naiset edustavat enemmistöä seksuaaliaktiivisesta nuorista/fertiili-
ikäisistä naisista. HPV vasta-aineiden tyyppispesifisyys ja stabiilius mahdollistivat 
analyysit HPV infektioiden kumuloitumisesta yli viiden vuoden aikana. Tutkimuk-
sellamme oli myös rajoituksensa, kahden työn poikkileikkausluonne ei mahdollista-
nut saatujen HPV-infektioiden järjestyksestä, eikä prospektiivisessakaan tutkimuk-
sessa tarkkaa infektion saantiajankohtaa voitu määrittää. Meiltä puuttui HPV DNA 
tiedot, ja CD4 määriä koskevat tietot, jotta olisimme voineet erottaa tuoreet HPV 
infektiot aikaisemmista infektioista, ja arvioida immuniteetin tilaa HIV-positiivisilla 
tutkittavilla.  
 
Tuloksemme osoittavat, että useiden HPV infektioiden riski on korkea naisilla, jotka 
ovat altistuneet yhdellekään HPV tyypille, mutta erityisesti tyypeille HPV16 ja 
HPV18. Virusten poistumiseen yksilöillä, joilla on useita HPV tyyppien aiheuttamia 
infektioita, vaikuttaa HIV positiivisuus. Tämän vuoksi ennaltaehkäisevät joukkoro-
kotukset ovat keskeisen tärkeitä kontrolloitaessa hrHPV tyyppien aiheuttamaa tauti-
taakkaan nuorilla naisilla, Uganda tapaisissa maissa, joissa HIV on endeeminen. 
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Tietoa HPV rokotteen tehosta ja siihen vaikuttavista tekijöistä Saharan alapuolisessa 
Afrikassa kaivataan kipeästi.  
 
Avainsanat: ihmisen papilloomavirus, HPV, vasta-aineet, immuunikatovirus, HIV, 
seroprevalenssi, serokonversio, vasta-aineen sitoumuskyky, raskaana oleva nainen 
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1 INTRODUCTION 
Cervical cancer (CC) is the third most common cancer among females worldwide 
with 529,800 new cases and 275,100 deaths in 2008 (Ferlay et al. 2010, Jemal et al. 
2011). The highest incidence (>80% of cases) and the highest mortality of CC occur 
in developing countries, most notably Sub-Saharan Africa (Sankaranarayanan  2006, 
Jemal et al. 2011, Arbyn et al. 2011) with no organized population based CC screen-
ing/treatment programmes. In the developing countries, most women only seek 
health care at the symptomatic/final stages of CC, which results in high mortality 
(Wabinga et al. 2003), while in the developed countries both incidence of and mor-
tality from CC have markedly decreased due to population-based organized cyto-
logical screening programmes (Bulk et al. 2005, Arbyn et al. 2007, 2009).  The inci-
dence of cervical adenocarcinoma (CA) is, however, on the increase, especially 
among young women (Bray et al. 2005, Bulk et al. 2005, Pettersson et al. 2011). 
Sampling of the columnar epithelial cells giving rise to CA is difficult with the 
available screening techniques and new oncogenic, high-risk (hr) human papillo-
mavirus (HPV) types infecting especially these cells have emerged (Bray et al. 2005, 
Castellsague et al. 2006). 
Genital infection with hrHPVs is very common (Koutsky 1997, de Sanjose et al. 
2007) with peak prevalence in women under 30 years of age (Kjaer et al. 2007, 
Smith et al. 2008). The most notable hrHPV types are 16 and 18 (Durst et al. 1983, 
Boshart et al. 1984). In 90% of immuno-competent individuals clear these viruses 
spontaneously within 18 months of infection (Bulkmans et al. 2007, Stanley 2010a).  
Persistent hrHPV infections in 10% of women may progress via various grades of 
cervical intraepithelial neoplasia (CIN) to cervical cancer (CC). HPV16 /18 are re-
sponsible for >70% of CC (Lehtinen et al. 2001, IARC Monograph 2007, Li et al. 
2011). 
 
Multiple genital HPV infections are common (Thomas et al. 2000, Rousseau et al. 
2003, Soto-De et al. 2011). Twenty to 50% of infected women harbour multiple 
hrHPV types (Liaw et al. 2001, Cuschieri et al. 2004, Clifford et al. 2005, Vaccarella 
et al. 2010, Chaturvedi et al. 2011, Weaver et al. 2011). Occurrence of multiple 
hrHPV types is associated with persistent infection and increased risk of cervical 
cancer (Ho et al. 1998, Kjaer et al. 2005, Trottier et al. 2006).  
 
Quadrivalent (HPV6/11/16/18) or bivalent (HPV16/18) virus-like particle (VLP) 
vaccines comprising the major L1 structural proteins of the non-oncogenic and/or 
oncogenic HPV types have been licenced (Markowitz et al. 2007, FDA 
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www.fda.gov/news release . 2010, EMA www.ema.europa. eu/ PDFs_Gardasil 2006 
accessed 2010, EMA, www.europa.eu/humandocs/PDFs/_ Cervarix 2007 accessed 
2010). They have both shown 100% immunogenicity and more than 90% efficacy 
against persistent HPV16/18 infections and HPV16/18 associated CIN2/3 (Harper et 
al. 2006, Villa et al. 2006a,b, Paavonen et al. 2009, Lehtinen et al. 2012) in the de-
veloped countries. The vaccines are being administered in developing countries 
(Anon 2011) but so far no HPV vaccine trials have been completed in Sub-Saharan 
Africa.  To establish most efficient mass HPV vaccination programmes in the latter, 
it is necessary to understand the distribution of HPV types and factors which may 
interfere with the immunogenicity and the efficacy of the vaccines in Sub-Saharan 
Africa.  
 
The stability of serum HPV antibodies makes serology a useful tool for epidemiol-
ogical studies on HPV occurrence. Concomitant seropositivity to multiple HPV 
types has been reported (Carter et al. 2000, Kaasila et al. 2009, Porras et al. 2010, 
Merikukka et al. 2011), but the protective role of antibodies acquired from natural 
HPV infections is unclear. Some studies have reported increased risk of acquiring 
new HPV infections in individuals exposed to one HPV type (Lehtinen et al. 2006, 
Kaasila et al. 2009, Merikukka et al. 2011) whereas others have reported protection 
against new infections (Ho et al. 2002, Malik et al. 2009). Factors affecting the co-
existence/acquisition of different HPV types need to be understood for optimal use 
of HPV vaccines (Tornesello et al. 2007).  
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2 LITERATURE REVIEW 
 
2.1 Biology of HPV  
Human papillomavirus is a member of the Papillomaviridae family as designated by 
the International Committee on Taxonomy of Viruses (ICTV) that infects only hu-
mans (ICTV Virus Taxonomy 2009). Like all papillomaviruses, HPV establishes 
productive infections only in the epithelium of the skin or mucosa. Molecular biol-
ogy has made it possible to study the interactions of viral gene expression and repli-
cation with the host cell phenotype (IARC Monographs 2007). Major breakthroughs 
in the understanding of the viral oncoprotein, most notably the E5/6/7 proteins, ac-
tivities of hrHPV types to the integrity of cellular DNA and cell-cycle control were 
made already in the 1990’s.  
 
2.1.1 Classification of HPV 
 
HPV belongs to the Papillomaviridae family (ICTV Virus Taxonomy 2009). Cur-
rently, 120 different HPV genotypes that infect humans have been classified (Ber-
nard et al. 2010) and are allocated a type number according to the order of discovery. 
The taxonomy is based on comparison of the nucleotide sequences and homology of 
the L1 ORF. A new type is named if the difference in the DNA sequence of the L1 
gene is > 10% from that of the closest HPV type known (de Villiers et al. 2004).  
 
Approximately 40 HPV types infect the epithelial lining of the anogenital mucosae 
and cause warts and cancerous lesions of the cervix, vulva, vagina and anus in 
women and the penis and anus in males (IARC monograph 2007, Stanley 2010b). 
The HPV types that belong to the genus Alphapapillomavirus are predominately 
detected in the mucosal epithelium (de Villiers et al. 2004).  The oncogenic HPV 
types associated with genital intraepithelial neoplasia and cancer are referred to as 
thirteen high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), these 
are further grouped according to their phylogenetic relatedness into clade A7 
(HPV18, 39, 45, 59, 68), clade A9 (HPV16, 31, 33, 35, 52, 58) and clade A5 
(HPV51, 69) species (de Villiers et al. 2004, Schiffman et al. 2009). Those HPVs 
found in benign genital warts (condylomata accuminata) are referred to as “low-
risk” (lr) types and belong mostly to clade A10 (HPV6, 11, 13, 44, 55) (Munoz et al. 
2003). 
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2.1.2 Structure and genome of the papillomavirus 
Papillomavirus is a small (52-55nm diameter), non-enveloped, epitheliotropic, dou-
ble stranded DNA virus. The virion comprises double-stranded DNA, and a capsid 
with the major (L1) and minor (L2) proteins of 55kDa and 70 kDa, which comprise 
80% and 20% of the total virion protein content, respectively (Doorbar 2005). The 
L1 and L2 proteins assemble into capsomers, during the generation of progeny viri-
ons (Fehrmann and Laimins. 2003). 
 
 
Figure 1. Genome structure of HPV 
 
 
The genome of all HPV types comprises eight open reading frames (ORFs) (E1, E2, 
E4, E5, E6, E7, L1, and L2) that are transcribed from a single DNA strand of about 
8,000 base pairs. There are three functional parts in the genome; the early (E) region 
that encodes the proteins (E1-E7) responsible for viral replication (E1, E2), tran-
scriptional regulation (E2) and cellular transformation (E5, E6, E7); the late (L) 
region that encodes the structural proteins (L1 and L2) that are necessary for virion 
assembly; and the long control region (LCR), which contains cis-regulatory ele-
ments that are necessary for the replication and transcription of viral DNA (Figure 
1). The viral proteins E1 and E2 act as factors that recognize the origin of replication 
and E2 is the major regulator of viral transcription. E4 encodes a protein required for 
final stages of replication, while the E5 protein functions in both early and late 
phases (Doorbar et al. 2005). The most important oncogenic HPV proteins are E6 
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and E7, which target a number of regulators of the cell cycle most importantly p53 
and p105Rb respectively (Münger and Howley 2002).  
 
2.1.3 Lifecycle of HPV 
 
Mechanisms of viral entry 
 
HPV replicates only in epithelial cells. The virus enters basal epithelial cells through 
micro-wounds or micro-abrasions. This is why early age at first sexual debut, 
coarsed sex and other sexually transmitted infections (STIs) enhance virus entry 
(Stanley 2010a). Receptors such as glycosaminoglycans (GAGs), most notably 
heparan sulphate proteoglycans (HSPG) which are frequently found in the extracel-
lular matrix (ECM) and on the surface of most cells, are suggested to be the sites of 
initial attachment for HPV virions (Sapp and Bienkowska-Haba 2009). Other studies 
suggest that the virus first binds heparan at the basement membrane, and later to a 
cellular receptor on the keratinocyte (Kines et al. 2009).  
 
HPV entry into the target keratinocyte is a very slow process, which can take up to 
12 hours (Sapp and Day 2009). The L1 antibodies can block the virus attachment, 
but may also interfere with post attachment interactions (Stanley 2010a). Neutraliz-
ing HPV L1 antibodies needed to block the basement membrane binding are effec-
tive at very low concentrations (Stanley 2010a). However, higher HPV antibody 
levels of high affinity are required for cross-protection. 
 
Viral replication 
 
Once inside the cell, the HPV life-cycle strictly follows the differentiation of the 
host keratinocytes. First, the viral DNA is uncoated and its genome is transported to 
the nucleus taking advantage of the cellular machinery to replicate its genome with a 
high degree of proof reading. In the nucleus, the viral DNA-binding proteins E2 and 
E1, responsible respectively for viral DNA transcription and replication are first 
expressed. At this stage, the infected cells usually contain small numbers of viral 
copies (10-200 copies per cell) (Doorbar 2007). The proliferating cells move to-
wards the outer layer of the epithelium, and the viral replication is strictly controlled 
to prevent the viral genome being amplified and expressed too early in order to 
avoid immune recognition. When the host keratinocyte reaches the S-phase in the 
differentiation compartment of the epithelium, viral E4 protein activates the produc-
tive phase of the viral replication and the genome copy number increases up to 1,000 
copies per cell. At this stage, the L1 and L2 genes are transcribed and the corre-
sponding proteins are translated and serve as structural proteins that assemble into 
capsids, which encapsidate the viral genomes forming the progeny viral particles. 
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The virions are sloughed off with the dead squamous cells of the host epithelium 
(Stanley 2007) for further transmission of the new virions (Figure 2). 
 
Figure 2.  Life cycle of genital human papillomavirus (Gynecol Oncol 2008; 109:s15-s21). 
Reproduced with permission from the publishers 
 
 
Viral transformation and oncogenic pathways  
 
In the replicative cycle the viral E5, E6 and E7 proteins responsible for the trans-
formation of infected cells are expressed in keratinocytes doomed to die. In contrast 
in the basal cells, the oncogenic E5, E6 and E7 genes are expressed to establish and 
maintain viral persistence in keratinocytes, which gradually turn from differentiating 
into transformed cells (Stanley 2010b).  
 
During the transformation process the E5 protein interacts with the 16kD subunit of 
the protein-pump ATPase, which inhibits the acidification of endosomes and the 
gap-junction intercellular communication in the keratinocytes. This facilitates acti-
vation of epidermal growth factor (EGF) receptor tyrosine kinase and its signaling 
pathway. Hence an increase in the mitogenic stimulus occurs following E5 expres-
sion from the growth factor receptor to the nucleus (DiMoio and Mattoon 2001, 
Auvinen et al. 2004). On the other hand, E5 also modulates expression of a number 
of host cell microRNAs, which suggests its role may be more complex (Greco et al. 
2011) 
 
E6 protein, in association with host E6-associated protein (AP), has ubiquitin ligase 
activity and ubiquitinates p53 to facilitate its proteosomal degradation. On the other 
hand, E7 protein of the oncogenic HPV acts as the primary transforming protein. E7 
protein competes for pRb binding, and enables transcription factor E2F to transacti-
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vate its targets, thus pushing the cell cycle forwards. The net effect shut off of the 
main cancer-controlling genes p53 and pRB leads to cellular transformation. 
 
2.1.4 HPV Transmission 
The main route for the transmission of genital HPV types is sexual contact. Ap-
proximately, 95% of individuals infected with genital HPV acquired the virus 
through sexual contact (Fairley 1993, Kjaer et al. 2001). Several studies have re-
ported sexual debut and number of sexual partners as the most notable risk factors 
for the acquisition of genital HPVs (Dillner et al. 1996, Auvinen et al. 2005, Barthell 
et al. 2009, Malik et al. 2009, Luovanto et al. 20. 2011). Hernandez et al. (2008) the 
estimated overall HPV transmission rate from penis to cervix and from cervix to 
penis, to be 60/100 and 210/100 person years respectively. In a longitudinal couple 
study the overall transmission probability was calculated to be 42% (95% CI 36-47) 
per partnership and 0.80% (0.6-1.0) per act (Burchell et al. 2006a,b, 2010). The 
highest prevalences of single and multiple HPV infections based on both HPV DNA 
and serology are found in young adult women under <30 years of age (Mendez et al. 
2005, Kaasila et al. 2009, Banura et al. 2010).  
 
Vertical transmission is an infrequent mode of HPV transmission. A study in Den-
mark showed that women who were virgins at baseline and engaged in sexual activ-
ity during follow-up, became HPV16 antibody and/or HPV16 DNA positive (Kjaer 
et al. 2001). There is, however, evidence that 15-18% of genital and 10-21% of oral 
HPV infections can be transmitted from an infected mother to an infant between 
birth and six months after delivery (Medeiros et al. 2005, Rintala et al. 2005).  
 
Sexual transmission in children associated with sexual abuse has been identified as a 
mode of HPV transmission. Increased numbers of HPV-infected children parallels 
the rise in childabuse cases in the US (Unger et al. 2011, Hobbs 2011). Non-sexual 
transmission also occurs, e.g. contact with infected urogenital secretions from shar-
ing towels or bathing together (Unger et al. 2011). Transmission probability esti-
mates for other than sexual transmission do not exist. 
 
 
2.1.5 Risk factors for genital HPV infections  
 
Potential risk factors for exposure to HPV are all related to sexual behaviour and 
viral entry facilitated by micro-wounds.  
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Since HPV is spread by skin/mucosa to skin/mucosa contact the potential factors of 
transmission are related to sexual behaviour, and anything which affects the integrity 
of the body surface causing micro-wounds may lead to increased acquisition of HPV 
(Almonte et al. 2008, Veldhuijzen et al. 2010, Louvanto et al. 2011a). Susceptibilty 
to the infection, however, depends on the host’s resistance because not all exposed 
persons become infected. The proximate determinants of genital HPV transmission 
are presented here. Co-factors/confounding factors, and host immune response are 
considerd together with the natural history of an established infection.            
 
Sexual debut There is evidence from follow up studies which shows that the first 
sexual intercourse is strongly associated with HPV infections. In follow-up studies 
young women who became sexually active tested HPV positive and those who re-
mained virgins remained HPV negative (Kjaer et al. 2001, Munoz et al. 2004, Niel-
sen et al. 2009). This is probably due to the micro-wounds easily caused in the im-
mature genital tract, and in most populations the incidences of genital HPV infec-
tions peak soon after sexual activity (Munoz et al. 2004, Nielsen et al. 2009, 
Luovanto et al. 2011, Banura et al. 2011).  
 
Number of sexual partners The association between the number of sexual partners 
and HPV acquisition has been commonly reported (Carter et al. 2000, Rousseau et al. 
2003, Nielsen et al. 2009, Banura et al. 2010, Luovanto et al. 2011a) and verified in 
a number of meta-analyses (de Sanjose et al. 2007, Bruni et al. 2010). Different 
individuals harbour different HPV types with different levels of viral load hence 
increased frequency of exposure to multiple sexual partners increases the risk of 
acquiring HPV infections. It is not clear whether the transmission of multiple HPV 
infections is simultaneous or serial. There is some evidence on concomitant acquisi-
tion of more than one type from several sexual partners (Rousseau et al. 2003).  
 
The male factor Studies from male cohorts show that HPV is highly prevalent in 
uncircumcised men and also men with multiple sexual partners (Castellsague et al. 
1997, 2002, Banura et al. 2011). 
Conversely, circumcision is associated with reduced risk of acquisition of STIs, 
especially HIV and HPV, both in men and in their sexual partners (Serwadda et al. 
2010, Wawer et al. 2011).  Irrespective of marital status men are regarded as reser-
voirs and vectors for HPV infections provided they have had many life-time sexual 
partners (Castellsague et al. 1997). The prevalence of STDs such as HIV and HPV 
has been reported to be high among women with cross-generation male sexual part-
ners and those in polygamous marriage (Kelly et al. 2003). Condom use, however, 
offers partial protection since HPV can be transmitted by the contact of the uncov-
ered skin (Winer et al. 2006). 
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2.2 Identification of HPV 
 
Because HPV infection can last for a long time in its nonproductive/asymptomatic 
stage, it is difficult for an individual to know if she/he is infected until the clinical 
symptoms occur, often from precancerous/cancerous lesions (Stanley 2007). So far 
the, available knowledge on hrHPVs has made it possible to detect the viral infec-
tion at early stage to prevent progression of the persistent infection to invasive cer-
vical cancer (ICC). Several direct and indirect methods have been developed to iden-
tify HPV.  
 
Direct tests for the presence of HPV DNA or protein(s)   
The following methods are based on the detection of nucleic acids (HPV DNA and 
HPV RNA) or the detection of HPV proteins in the infected tissues by specific anti-
bodies. 
 
HPV DNA detection 
Over the years several techniques have been developed to detect HPV infections 
using nucleic acid hybridization. These include; Southern blot, dot blot, in situ hy-
bridization, hybrid capture II and polymerase chain reaction (PCR). The last two are 
currently the most widely used methods for the detection of HPV DNA. 
 
Polymerase chain reaction is widely used due to its high sensitivity and specificity 
in HPV detection. It is a selective DNA-target amplification assay that is capable of 
exponential and reproductive increase in the HPV sequences present in the biologi-
cal specimens (Brink et al. 2007). Theoretically, it can produce up to a billion copies 
from a single-stranded DNA molecule in 30 cycles of amplification. There are varia-
tions in the sensitivity and specificity of PCR depending on the site and type of col-
lected samples, their storage and transportation, procedures of DNA extraction, 
primer sets, size of the PCR product, the PCR reaction conditions and performance 
of the DNA polymerase used in the reaction, as well as the spectrum of HPV types 
amplified, and the ability to detect multiple types (Brink et al. 2007). Most HPV-
PCR assays utilize consensus primers (such as GP5/6 and/or its modified extended 
version GP5+/6+, the MY09/11 pair of degenerate primers and its modified version 
PGMY09/11 and SPF10 system), directed at the conserved parts of the L1 gene and 
this allows detection of all mucosal HPV types (Karlsen et al. 1996). Amplification 
with each of these primers will result in different size amplification products (ampli-
cons), and different sensitivities in the detection of certain HPV genotypes. (Manos 
et al. 1989, de Roda Husman et al. 1995, Jacobs et al. 1997, Kleter et al. 1998, Gra-
vitt et al. 2000, Kornegay et al. 2001). The efficiency of amplification with these 
validated primers as well as comparisons of their performance has been widely re-
ported (Gheit et al. 2006, Galan-Sanchez et al. 2009, Barcellos et al. 2011). Al-
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though there is general agreement in performance, the different HPV-typing assays 
have good agreement in infections with single types but poor agreement in infec-
tions with multiple HPV types (Brink et al. 2007, Sabol et al. 2008, Roberts et al. 
2011).  
 
Multiplex HPV genotyping is bead-based quantitative and high-throughput DNA-
hybridization method that uses the Luminex suspension array technique to simulta-
neously detect and genotype up to 100 HPV types (Schmitt et al. 2006). This method 
is based on the amplification of a sequence of HPV DNA (in the L1 gene) identified 
by the consensus primers GP5+/6+ and the subsequent detection of the amplicons 
with type-specific oligonucleotide probes coupled with fluorescence-labelled poly-
styrene beads with a diameter of 5.6 μm that are internally dyed with various ratios 
of two spectrally distinct fluorophores, creating an array of 100 different bead sets 
with specific absorption spectra (Louvanto et al. 2010a, b). It has a comparable prin-
ciple to that of Multiplex HPV serology. 
 
The Hybrid Capture II assay (Digene) is commercially available. It is a nucleic 
acid hybridization assay with signal amplification that utilizes microplate chemilu-
minescent detection. The assay is highly sensitive and can detect DNA for 13 high-
risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and five low-risk (6, 11, 42, 
43, 44) HPV types (Clavel et al. 1998, Chaudhary et al. 2010). Despite its good 
performance as a triage test it is not a sensitive or type-specific assay.  
 
HPV RNA detection 
The detection of hrHPV type E6/E7 is strongly associated with the progression of 
HPV-associated neoplasia because the proteins induce malignant transformation 
(Halfon et al. 2010). These tests are commercially available and detect E6/E7 
mRNAs of 14 hrHPV types (Castle et al. 2007, Tropé et al. 2009), but have not yet 
been approved for diagnostic screening by the FDA.   
 
The limitations of the nucleic acid tests are that they differ in sensitivity and some 
tests may overestimate the prevalence/incidence of hrHPV types due to high sensi-
tivity. Also, contamination can easily occur during the PCR process. On the other 
hand, detecting only current infections may underestimate the HPV exposure. Since 
a HPV DNA test is suggested to be included as a primary screening test in the pack-
age of CC screening/treatment programmes, WHO is working on the protocol for 
the international standardization (IS) of  HPV DNA tests in their reference labs 
(Labnet (WHO HPV- Labnet Newsletter 6. 2010, Wilkinson et al. 2010). 
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Tests for the detection of HPV-induced antibodies  
 
HPV serology is essential for both epidemiological studies and for monitoring of 
HPV vaccine imunogenicity but not for diagnostic purposes due to the absence of 
antibody response in a proportion of genital HPV infections. It measures antibodies 
against specific HPV types stemming from past or present infections or derived from 
HPV vaccination. Several methods have been used to detect HPV antibodies in the 
past but the sensitivity and specificity of the tests were poor, largely due to the 
suboptimal methodology. This affected the progress in HPV serology work for a 
decade (Dillner et al. 1996).  
 
The discovery that capsid proteins of HPV produced in insect cells self-assemble 
into virus-like particles (VLPs) from the L1 protein (Kirnbauer et al. 1994; Carter et 
al. 1995) provided an invaluable tool for HPV serology and for the development of 
prophylactic HPV vaccines (Lowy and Schiller 2006). VLPs have features that in-
clude the display of type-specific common surface-exposed neutralizing epitopes 
and are suitable for use in enzyme immunoassays (Schiller et al. 1996, Kirnbauer et 
al. 1994, Dillner 1999,).  
 
The use of VLPs led to fast progress in seroepidemiological HPV studies (Lehtinen 
et al. 1996, Dillner et al. 1997, Mork et al. 2001, Lehtinen et al. 2006). There is good 
evidence that HPV antibodies are type specific; e.g. against HPV6/16/18 capsids 
(Carter et al. 2000). Pre-adsorption experiments showed that sera reacting with mul-
tiple capsids contained multiple type-specific antibodies rather than cross-reactive 
antibodies. These studies also showed a strong correlation shown between seroposi-
tivity to a specific HPV type and detection of the same type HPV DNA (Kirnbauer 
et al. 1994, Carter et al. 2000). Because HPV antibodies are stable over five years 
(af Geijersstam et al. 1998) and they are suitable immunological markers for cumu-
lative exposure (past and current)  to HPV infections.  
 
The methods successfully used in HPV serology are VLP-based ELISA, pseudo-
virion-based neutralisation assay, Luminex assays, and Multiplex serology assays. 
 
Enzyme linked immunosorbent assay (ELISA) based on VLPs is the most com-
monly used method in HPV seroepidemiology and HPV vaccine studies. In ELISA, 
a known amount (concentration) of type-specific HPV VLP (antigen) is affixed to 
the surface of a microtitre plate, and then a known standardized amount of serum 
with unknown amount of antibodies is applied. Known amounts of secondary anti-
body linked to an enzyme are then added, and in the final step a standard substrate is 
added for the enzyme to convert to a detectable signal (colour change). The reaction 
is stopped and read with a microplate reader and the colour change is quantified. 
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Due to the conformational integrity of the antigenic VLP epitopes this method is 
type-specific (Dessy et al. 2008). It detects total immunologloblin G (IgG) or IgA 
but does not distinguish between neutralizing and non-neutralising antibodies 
(Dessy et al. 2008). Its sensitivity ranges between 50 and 70% and specificity 95%-
99% (Dillner et al. 1996, Kjellberg et al. 1999). VLP-based ELISAs have been used 
in a number of epidemiological studies (Lehtinen et al. 2006, Simen-Kapeu et al. 
2008, Kaasila et al. 2009, Merikukka et al. 2011).  
 
Multiplex serology based on glutathione S-transferase fusion-protein capture on 
fluorescent beads, detects antibodies against several specific HPV types simultane-
ously. It measures total IgG concentrations and does not distinguish between neu-
tralizing and non-neutralizing antibodies. It is more sensitive than direct standard 
ELISA it can detect HPV16 E6 antibodies (Waterboer et al. 2005, Micheal et al. 
2008, Clifford et al. 2007, Dondog et al. 2008). This method has also been used in a 
number of seroepidemiological studies (Waterboer et al. 2005; Waterboer et al. 2006; 
Syrjänen et al. 2009, Michael et al. 2010) 
 
The interpretation of HPV serology results depends on individual in-house controls. 
For the comparability and reliability of serological data an international standardisa-
tion, particularly in terms of antibody units is required. WHO in collaboration with 
the National Institute for Biological Standards and Control (NIBSC), established the 
first IS for anti-HPV 16 serum (product no.05/134) (Ferguson et al. 2006) . This will 
serve as the primary biological standard for antibodies to HPV16 and may be used in 
the immunoassays utilizing VLPs and neutralizing assays utilizing pseudovirions 
(PsVs). The IS for other HPV types, e.g. HPV18 are in preparation (WHO HPV- 
Labnet Newsletter 06, 2010). 
 
Other indirect methods for diagnosing HPV infection 
The effects of the virus on mucosal cells have been used for indirect diagnosis of 
HPV infections. 
The Pap test, the gold standard for detecting abnormal cell changes in the uterine 
cervix due to HPV was developed by Dr G. Papanicolaou in the 1920s (Carmichael 
1973). Cells are collected from the outer opening of the cervix and the endocervix 
(transformation zone) using a speculum and /or brush and fixed on a glass followed 
by examination under a microscope to look for abnormalities. The test aims to detect 
potentially pre-cancerous changes, which could be removed. It is the most widely 
used test in screening for CC worldwide. In America, the Pap test has reduced the 
incidence of CC from 40/100,000 to 8/100,000 women. In Finland, Sweden, British 
Columbia and Canada, the incidence of CC has decreased up to 70-80% (Hakama 
1982, Nieminen et al. 1995, Hristova and Hakama 1997, Nieminen et al. 1999). It 
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has been observed that the introduction of the Pap test in a population which has 
never been screened for CC (like Uganda) may reduce the risk by 60-90% among 
women over 25 years of age (IARC 2005). Although the Pap test is a gold standard, 
if done once it has a sensitivity ranging from 50-80%. Hence repeated sampling 
following an organized programme is crucial.  
 
Liquid-based cytology (LBC) is a modification of Pap smear cytology, applying 
plastic sampling devices (Karnon et al. 2004). The cells are suspended in the collec-
tion medium and a thin layer of cells is fixed on the slide. LBC has been widely 
accepted as the primary tool in CC screening. (Nieminen et al. 2007, Arbyn et al. 
2008, Gibbs and Marten 2011, Anttila et al. 2011). Liquid-based cervical cytology 
has been reported to markedly reduce the numbers of unsatisfactory slides (Beerman 
et al. 2009), but the sensitivity and specificity for the detection of high-grade cervi-
cal intraepithelial neoplasia is very close to that of conventional cytology test (Ar-
byn et al. 2008). 
 
In visual inspection after application of acetic acid (VIA) or Lugol’s iodine (VILI) 
the cervix is examined with naked eyes or with a hand–held magnifying device. The 
reporting depends on the colour changes. VIA was one of the first CC screening 
tests. It was introduced by Schiller in the 1930s (Schiller 1938). Although Schiller's 
test had poor specificity and was almost entirely replaced with the advent of cervical 
cytology, it was revived to be used in developing countries. In India, a single screen 
with VIA achieved a reduction in the CC incidence by 25% and CC mortality by 
35% (Sankaranarayanan et al. 2007). Several other developing countries have started 
using the VIA in combination with other tests such as the Pap smear test for CC 
screening (Muwonge et al. 2010). VIA is cheap and easy to perform, it gives imme-
diate results, has high sensitivity (96.7%), but contributes to high numbers of false 
positives due to low specificity (36.4%) compared to conventional cytology (Goel et 
al. 2004).  
 
2.3 Epidemiology 
2.3.1 Occurrence of genital HPV infections 
The life-time risk of HPV infection is 80% (Syrjanen et al. 1990). The age-specific 
HPV prevalence  peaks at younger ages (< 30 years) worldwide, then a consistent 
age-related decline in HPV prevalence and plateau between 35- 40 years, and in the 
Americas, Africa and Europe, a clear second peak at 45 years has been documented 
(Herrero et al. 2005, de Sanjose et al. 2007, Smith et al. 2008, Bruni et al. 2010). In 
prospective studies, the first peak is reported shortly after sexual debut for most 
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women, and is generally attributed to higher levels of sexual activity with multiple 
partners or partners with risky sexual networks, immature mucosal epithelial layers 
and to low viral immunity (Kjaer et al. 2000, Carter et al. 2000, Viscidi et al. 2004, 
Auvinen et al. 2005, Banura et al. 2011, Weaver et al. 2011). While the overall, 
country-specific HPV prevalence values are more or less comparable, the age-
specific prevalences are higher in developing countries than in the developed coun-
tries (Smith et al. 2008, Bruni et al. 2010).  
 
The age-specific genital HPV DNA prevalence among women under 25 years was 
reportedly 20% in Africa, America, and Latin America while in Europe and Asia it 
was 15% in a review article (Smith et al. 2008). However, within regions country-
specific variations were observed. In Africa the prevalence ranges between 2% and 
60% with the highest prevalence found in the East African countries, Kenya, Mo-
zambique, Tanzania and Uganda (Smith et al. 2008). In Uganda the prevalence of 
HPV among women aged under 25 years, ranges between 23.7% and 67.1% in HIV 
negatives and 41.6% -75% in HIV positives (Banura et al. 2011). Whereas in Fin-
land the HPV prevalence among female university students was 33% and out of 
these 82% had hrHPV types (Auvinen et al. 2005). Among women aged 25-29 years 
in a population-based cervical cancer screening programme HPV prevalence was 
24.1 % (Leinonen et al. 2008). 
The prevalences of genital HPV DNA depend on the sample collection method and 
site and on the test used, as some are more sensitive than others, and the study popu-
lation, which is why age is important factor in reporting HPV prevalence because 
different age groups are engaged in different risky sexual behaviours. It is well 
known that 90% of infected women clear their viruses within two years (Carter et al. 
2000, Banura et al. 2010, Luovanto et al. 2010b). Hence the DNA prevalence may 
be underreported in some cases.  
 
2.3.2 Seroepidemiology of HPV  
HPV DNA data has been widely used to describe the epidemiology of HPV, how-
ever, there are some limitations related to HPV DNA detection. HPV infections are 
transient, and the time and site of sample collection are crucial. HPV serology is 
therefore an important epidemiological tool for the detection of past and current 
HPV infections and for estimating HPV-associated neoplasia risk. The natural his-
tory of HPV antibodies is well studied (Ho et al. 1998, Porras et al. 2010). Up to 
70% of HPV infected individuals seroconvert to a detectable level (Ho et al. 1998, 
Kjellberg et al. 1999, Carter et al. 2000) and antibodies once detected last for more 
than 5 years (Carter et al. 1996, af Geijersstan et al. 1998). Seroconversion takes 
from some 8 months to years (Ho et al. 2002), however type-specific studies indi-
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cate that lrHPV types seroconvert faster than hrHPVs (Carter et al. 1996, 2000, Syr-
janen et al. 2009). HPV antibody positivity is strongly associated with lifetime num-
ber of sexual partners (Dillner at al. 1996, Viscidi et al. 1997, Lehtinen et al. 2006, 
Porras et al. 2010), which suggests that sexual contact is still the main route of HPV 
transmission. Transmission through other routes is very low (Sarkola et al. 2008a, 
2008b) 
HPV serology identifies both past and current infections (cumulative incidences) 
which makes it a suitable immunological tool to monitor HPV prevalence and inci-
dence in the population and it is used to predict the future burden of CC (Lehtinen et 
al. 2006, Kaasila et al. 2009). Seroepidemiological studies on the occurrence of 
common HPV types in populations are well documented in most developed coun-
tries (Dillner et al. 1996, Carter et al. 2000, Lehtinen et al. 2001, 2006, Ho et al. 
2002, 2004, Simen-Kapeu et al. 2008, Kaasila et al. 2009, Syrjanen et al. 2009, 
Merikukka et al. 2011). Serological studies have extensively documented the natural 
history of HPV16, 18 and 6 (Carter et al. 1996, 2000, Ho et al. 2002, Syrjanen et al. 
2009). Variations in seroprevalences have been reported to range between 1.6 and 
44% for HPV16, and 4.2% to 35.6% for HPV18. The determinants of HPV sero-
positivity included age, level of education, use of oral contraceptives; number of 
lifetime sexual partners (Ho et al. 2004, Wang et al. 2004, Lehtinen et al. 2006, Syr-
janen et al. 2009, Porras et al. 2010). Unfortunately, data are still limited in Sub-
Saharan Africa, especially in countries where HIV and other tropical infections are 
endemic. For instance, in a review of Ugandan HPV studies only two out of the 22 
HPV studies documented till 2010 reported HPV antibodies (Banura et al. 2011).  
 
2.3.3 Multiple HPV infections  
The proportion of women harbouring multiple (at least two) HPV infections among 
those infected with HPV ranges between 20 and 50% (Franco et al. 1999, Liaw et al. 
2001, Nielsen et al. 2008, Pista et al. 2011). The recent increase in multiple HPV 
infections is basically due to improved technology such as polymerase chain reac-
tion (PCR)-based methods using L1 modified general primers (MY11/GP6+ and 
GP5+/GP6+) in combination with type-specific (TS) E7 primers (Huang et al. 2004, 
Schmitt et al. 2006, Mejlhede et al. 2009, Schmitt et al. 2010). Multiple HPV infec-
tions are strongly associated with young age, below 30 years, increased number of 
sexual partners, uncirmucised partner and HIV infections (Clifford et al. 2005, Niel-
sen et al. 2008, Pista et al. 2010, Banura et al. 2011). In a meta-analysis, 3.2% of 
women with normal cytology (20% of those HPV positive) had multiple HPV infec-
tions (Bruni et al. 2010). Multiple HPV infections are on the increase in Africa, 
Europe and Oceania and declining in Asia and North America (Smith et al. 2007, de 
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Sanjose et al. 2010). These differences could be due to different study populations, 
number of studies conducted on each continent, methods of HPV detection and other 
factors.   
 
Seropositivity to multiple HPV types has been frequently reported (Carter et al. 
2000, Lehtinen et al. 2006, Kaasila et al. 2009). The possibility of some hrHPV 
types having a competitive advantage over other types has been suggested in popula-
tion-based longitudinal studies (Merikukka et al. 2011). Our current seroepidemiol-
ogy study focuses on some of those issues among Finnish and Ugandan women.   
 
2.4 Immune system and genital HPV infections  
 
2.4.1 Innate immunity and HPV infection  
 
Innate immunity is included in the basic resistance to infectious agents that an indi-
vidual encounters. Innate immunity provides the first line of defensive host response 
and eliminates most of the microorganisms encountered by a healthy individual. 
HPV cannot penetrate the basal membrane or infect stromal or other underlying cells 
without a micro-wound (Stanley 2010a). On the other hand, the virus has receptors 
that can infect only mucosal cells. Thus, the line of protection against HPV infection 
is the intact mucosa and skin whose basal cells are the innermost cells targeted by 
HPV. 
 
In the primary foci HPV remains exclusively intraepithelial and its replication takes 
place in a differentiation-dependent manner in the keratinocytes. HPV is not cyto-
lytic and no immediate inflammation accompanies viral infection and replication. 
This impairs the efficacy of the innate immune response. Antiviral and antiprolifera-
tion responses, however, take place, whereby keratinocytes secrete various cytokines 
(e.g. tumour growth factor beta (TGF- β), tumour necrosis factor alpha (TNF- α), 
and interferon alpha and beta (IFN-α and -β)) which regulate HPV infected cells 
(Stadnyk 1994, Wang et al. 1999).   
 
2.4.2 Adaptive immunity and HPV infection 
Adaptive immunity is initiated by the recognition of a foreign antigen and represents 
the response of the immune system to this recognition. It is antigen specific, diverse, 
comprises immunologic memory, and distinguishes self from non-self antigens. The 
immune system fights the HPV invasion in: cell mediated immune response and 
humoral immune response. In 90% of HPV infected subjects, the response is suc-
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cessful as judged by clearance of the virus (Bulkmans et al. 2007, Stanley 2010a). 
The interaction of cytokines/chemokines liberated during cellular immune reaction 
regulates the immune control of lesions associated with HPV.  
 
2.4.3  Cell-mediated immunity (CMI) and HPV infections  
Cell-mediated immunity is based on T lymphocytes of two types: T helper cells and 
cytotoxic T cells. When a T helper cell interacts with a microbial antigen-MHC II 
molecule complex present on an antigen presenting cell (APC), it becomes activated 
and begins to secrete cytokines. In general, depending on the activated T helper cell 
type Th1 or Th2, these cytokines activate cytotoxic T cells or B cells, in addition, 
various phagocytic cells are activated.  
When a cytotoxic T cell interacts with the microbial antigen-MHC I complex, it is 
activated under the influence of cytokines produced by already activated T helper 
cells. Then the activated cytotoxic T cells differentiate into cytolytic T lymphocytes 
(CTLs). The CTLs kill infected cells displaying an antigen-MHC I molecule. To-
gether, T helper cells and CTLs are modulators and effectors of the cell-mediated 
immune response. 
 
HPV does not enter the bloodstream, and the viral antigens expressed/released on 
the mucosal surfaces elicit the immune response (Stanley 2007).  The cervical epi-
thelium contains a variety of cells which, after coming into contact with the HPV 
antigens, are able to present fragments, mostly short peptides derived from cleaved 
viral proteins on the cell surface (Gonçalves and Donadi 2004). Antigen presenting 
cells (APCs), such as dendritic cells (Langerhans cells) and macrophages, activate 
the T-helper type-1 cells, which in turn activate the CTLs to destroy the virus-
infected cells. T-helper type-2 cells activate B cells, which produce antibodies and 
activate the complement mechanism. Several chemokines and cytokines which 
stimulate or suppress the pathways are released by the Th2 cells.  
 
In natural HPV infection, cell-mediated immunity works hand in hand with the in-
nate immunity to clear the virus-infected cells from pre-cancerous lesions usually 
within 18 months of acquisition of the infection (Frazer et al. 2009). Evidence of 
effective cell-mediated immunity has been found in 90% of HPV infected individu-
als who clear the virus within 18 months (Scott et al. 1999). Persistent infections 
with oncogenic HPV types, however, tend to suppress the cell-mediated immune 
response. On the contrary, in immune-suppressed individuals there is an increased 
prevalence of persistent, and in the long run also multiple HPV infections (Clifford 
et al. 2006, Banura et al. 2011). 
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Evidence from immune-suppressed individuals such as HIV positives, those with 
inherited immune deficiencies, renal transplant recipients, and patients on chemo-
therapy shows that T helper CD4 cells play the key role in controlling HPV infec-
tions and related neoplastic progression (Clifford et al. 2006). Clinical studies have 
reported cutaneous and genital warts among immuno-suppressed individuals (Palef-
sky 2006, Lutzner 1985, Leigh et al. 1995). In meta-analyses the prevalence of geni-
tal HPV infections in HIV-positive women has been consistently reported more than 
twice as often as in HIV-negative women (Cu-Uvin et al. 1999, Palefsky et al. 1999). 
Prospective studies have shown incident HPV infections and HPV persistence dou-
bling among women with CD4 cell count less than 200 cells/uL compared to women 
with more than 500 cells/uL (Ahdieh et al. 2001, Strickler et al. 2005). Poor clear-
ance of HPV infections among HIV infected individuals has been reported (Banura 
et al. 2010). Co-infections with multiple HPV types were found in 20% to 50% of 
HIV-infected women (Liaw et al. 2001, Clifford et al. 2005, 2006).  
 
Although multiple oncogenic HPV types are common among HIV positives, the 
association between markers of HIV disease status (such as viral load and CD4 lym-
phocyte count) and HPV infections is inconsistent. Some studies suggest that HPV 
prevalences were higher in the late stages of HIV disease (Ahdieh et al. 2001, 
Strickler et al. 2005), whereas other studies suggest that the occurrence of HPV 
infections and SIL are influenced by the HIV status independently of CD4 counts 
(Vernon 1999, Moscicki et al. 2000).  
 
2.4.4 Humoral response and HPV infections  
The humoral response is based on antibodies produced by antigen-activated and T 
helper cell stimulated B cells. Antibodies bind to the antigens and facilitate their 
elimination, e.g by forming clusters or rough cross linking of antigen molecules, 
which are then ingested by phagocytic cells. Antibody binding to a microorganism 
may activate the complement system to lyse the microorganism. Most importantly, 
antibody binding to virions prevents subsequent viral binding to host cells.  
 
In natural HPV infections antibody production is a very slow process, which may 
take several months to years and up to 50% of infected individuals may never sero-
convert (af Geijersstam et al. 1998, Carter et al. 1996, 2000, Syrjänen et al. 2009). 
The transient nature of HPV infection may not allow enough time for the HPV anti-
bodies to develop (Carter et al. 2000).  Antibody levels produced in natural HPV 
infections are generally low, probably due to the immune evasion strategies of the 
virus (Stanley 2010). Continuous HPV exposure has been reported as a risk factor 
for HPV seropositivity (Carter et al. 1996, 2000, Porras et al. 2010) which has been 
considered to be a marker of persistent HPV infection (Dillner et al. 1999). HPV 
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antibodies, once detected, remain stable for at least 5-10 years mainly for the hrHPV 
types (af Geijersstam et al. 1998, Kjellberg et al. 1999, Carter et al. 2000). This 
makes HPV antibodies a good immunological marker of cumulative HPV incidence 
(past and/or present infections) for epidemiological studies.  
 
Follow-up studies have reported that antibodies to lrHPV types rise faster to a de-
tectable level than antibodies to hrHPV types (Carter et al. 2000, Ho et al. 2004). 
While seroreversion for lrHPV types may occur faster than for hrHPV types (Carter 
et al. 2000), total antibody decay is rare for both lr and hr HPV types (af Geijersstam 
et al. 1998, Laukkanen et al. 2003, Kaasila et al. 2009, Syrjänen et al. 2009). Unlike 
other infections, where antibodies seem protective against re-infections, antibodies 
induced in natural HPV infections may not be protective against new infections (Ho 
et al. 2004) due to low antibody titres. In HPV vaccinated individuals, high antibody 
titres are easily transduced to mucosa (Petaja et al. 2010) where neutralization and 
blocking of the viruses take place.  
 
HPV seropositivity is a risk indicator for seroconversion to other different HPV 
types (Carter et al. 2000, Ho et al. 2004, Kaasila et al. 2009, Merikukka et al. 2011) 
most probably due to underlying risk behaviour (Dillner et al. 1996). Some studies 
have reported persistent HPV antibodies to be protective against new infections of 
the same or different HPV types (Ho et al. 2002, Viscidi et al. 2004, Malik et al. 
2009), however, seroconvertants have remained susceptible to subsequent reinfec-
tion with the same HPV type (Schwarz and Leo 2008, Viscidi et al. 2005). Identifi-
cation of a threshold level for the protective level of natural HPV infection induced 
antibodies, and for how long this kind of antibody response can offer protection 
warrant further studies.  
 
2.4.5 Seroconversion 
A successful immune response is characterized by seroconversion, i.e. production of 
antibodies against a specific antigen. HPV seroconversion takes several weeks to 
years depending on the individual immune status (Carter et al. 2000, Ho et al. 2004, 
Syrjanen et al. 2009). Approximately 50% of HPV16 DNA positive women sero-
convert (Kjellberg et al. 1999, Carter et al. 2000, Syrjänen et al. 2009). Seroconver-
sion to HPV16 and 18 has been reported to require persistent HPV DNA positivity, 
whereas for HPV6 seroconversion, transient HPV DNA positivity alone was enough 
(Carter et al. 2000). The risk of seroconversion for hrHPV types was associated with 
young age at sexual debut, increased life-time number of sexual partners, seroposi-
tivity for any type at baseline, and HPV DNA positivity at baseline (Carter et al. 
2000, Lehtinen et al. 2006, Kaasila et al. 2009, Syrjänen et al. 2009).  
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2.4.6 Maturation of the HPV antibodies  
The functionality of the immune response induced antibodies in natural HPV infec-
tions may vary. In general, neutralizing IgG HPV antibodies are considered to have 
high avidity (Wang and Hildesheim 2003), and the maturation antibody avidity cor-
relates with the ability to neutralize the infection (Nair et al. 2009). Low antibody 
avidity has been associated with poor protection against several viruses in immuno-
suppressed individuals (Nair et al. 2009) 
 
Maturation of IgG avidity and associated protection depends on the interplay be-
tween T-helper cells and B cells (Stavnezer et al. 1996, Gulbranson-Judge et al. 
1997, Bachmann et al. 1997, Nakanishi et al. 2009). The fact that high avidity anti-
bodies are usually detectable six months post primary infection has been success-
fully used in the distinction of acute, recent and past infections with e.g.  cytomega-
lovirus, Epstein-Barr virus, measles, parvovirus, rubella and toxoplasmosis) (Hed-
man et al. 1988, 1989, Söderlund et al. 1995, Aalto et al. 1998, Paunio et al. 2003). 
Sometimes the low-avidity antibodies can persist for months or years post primary 
infection among the immuno suppressed individuals (Bodeus et al. 1998, Lazzarotto 
et al. 1998).  
 
Under normal circumstances, T-helper cells recognize antigen and induce antigen-
primed B cells to produce high affinity antibodies. Therefore in a situation where T 
helper cells are deprived or not presented with the antigen by APCs, maturation of 
avidity may take a long time as observed in HIV and organ transplant patients 
(Brinkman et al. 2003, Nair et al. 2009). In natural infections the slow maturation of 
antibody avidity may correlate with impaired protection against the infection, and 
may increase the likelihood of multiple HPV infections with HPV types that have 
shown poor viral clearance (Banura et al. 2010, Luovanto et al. 2010).  
 
The reasons why HPV antibodies induced in natural HPV infections do not remain 
protective against subsequent infections with the same HPV types are not clear. 
Equally unclear is why some individuals acquire multiple HPV infections despite 
the presence of at least partially cross-reactive antibodies (Carter et al. 2000, Syr-
janen et al. 2009, Kaasila et al. 2009, Parros et al. 2010). Some studies suggest that 
inadequate avidity of the antibodies may play a role here (Bachmann et al. 1997, 
Wang and Hildesheim 2003).  
2.4.7 Immune evasion strategies 
In the infected cell HPV may go unrecognized by the immune system due to its 
evasion strategies, which include being restricted to mucosal surfaces, not being 
cytolytic, sequential downregulation of cellular signatory proteins for immune re-
sponse (MHC-1 antigens and cytokines) and low level of viral protein expression. 
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Viral DNA replication and virion assembly occur in cells already programmed to 
death, so there is no danger signal to alert the immune system (Stanley 2010b). The 
Langerhans cells are also depleted from HPV16 infected mucosal surfaces (Lehtinen 
et al. 1993). Furthermore, interferons  (IFN), which are key to antiviral defence are 
actively suppressed with the E6 and E7 proteins of the hrHPV, in turn inhibiting the 
IFN-gamma receptor signalling pathway and activation of  immune response genes 
(Doorbar. 2005, Pett et al. 2006, Kanodia et al. 2007, Ghittoni et al. 2010).  
 
HPV escapes from the immune surveillance through different mechanisms: using 
the host-cell machinery for replication, maintaining a small number of viral copies 
or expressing very low numbers of viral proteins in the basal cells of the stratified 
epithelium. To reduce the recognition of infected cells by antigen-presenting cells, 
HPV downregulates the expression of cell-surface signalling molecules that kerati-
nocytes express to limit the activation of cytotoxic T cells which kill the infected 
cells (Scott et al. 2001, Einstein et al. 2009). For instance, viral E7 protein also 
downregulates TLR9 (Hasan et al. 2007). Although the lack of MHC class I antigens 
may activate the natural killer cells (NK) only a few NKs patrol the upper epithelial 
layers, and the prospects for persistently infected cells to evade the host’s immune 
surveillance are good. 
 
There is experimental evidence that prior natural infection may interfere with vac-
cine-induced immunity at the level of clonal B-cell selection (McHeyzer-Williams 
2005). This could also be true in the case of subsequent infections with the same or 
closely related HPV types. The T-helper cell support for immunity is influenced and 
perturbed by age, persistence of the antigen and the immune response to natural 
infection at other anatomical sites (Fazilleau et al. 2007, Brink et al. 2008).  
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2.5 Natural history of genital HPV infections 
 
2.5.1 Incident HPV infections 
Human papillomavirus is the most common sexually transmitted infection with an 
80% lifetime risk of infection (Syrjänen et al. 1990). The incubation period of geni-
tal HPV infection to the first manifestations of the infection is 3-4 weeks (Stanley 
2010).  HPV infections clear spontaneously within 4 to 9 months (lrHPV) and 12 to 
18 months) in 90% of immunocompetent individuals (Figure 3). In the remaining 
10% the infection persists and may progress via various stages to genital warts 
(lrHPV) or CC (hrHPV) (Bosch et al. 2008). The peak period of HPV acquisition is 
soon after the first sexual intercourse (Kjaer et al. 2001, de Sanjose et al. 2007, 
Bruni et al. 2010) between the ages of 18 to 22 years (Smith et al. 2008), but the 
hrHPV infection incidences remain high and multiple infections occur in young 
adult women aged <30 years (Lehtinen et al. 2006, Nielsen et al. 2008, Smith et al. 
2008, Kaasila et al. 2009, Bruni et al. 2010). The incidences, however, decrease and 
prevalences/seroprevalences level out after 25-30 years of age (Clifford et al. 2005, 
de Sanjose et al. 2007, Smith et al. 2008, Bruni et al. 2010, Li et al. 2011) 
A secondary peak among >45 years has been observed in a few countries (Munoz et 
al. 2004, de Sanjosé et al. 2007, Bruni et al. 2010, Liu et al. 2011). The reasons for 
the second peak are unclear, but after the age of 45 years women may be susceptible 
to persistent HPV infections like young women due to hormonal imbalances which 
lead to cervical ectopy. 
 
2.5.2 Persistent lrHPV infections 
Persistent lrHPV types 6 and 11 induce proliferation of squamous epithelia to benign 
tumours (external genital warts, also known as condyloma accuminata). The lrHPV 
types are common and peak in young women aged 15-24 years.  Disease burden of 
benign warts associated with lrHPV is very common and there are differences in the 
geographical distribution of incidence rates (Kliewer et al. 2009, Kraut et al. 2010). 
A study in the Scandinavian countries showed that HPV6 and 11, which are respon-
sible for genital warts, are the most common sexually transmitted infections with a 
10% risk of lifetime acquisition (Kjaer et al. 2007). In West Africa (Burkina Faso) 
the prevalence of HPV6 and HPV11 was 6% and 4% respectively, and the genital 
warts were primarily associated with HPV6 (Low et al. 2010).   
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2.5.3 Persistent hrHPV infections  
Persistent hrHPV infections precede the development of squamous intraepithelial 
lesions and cervical neoplasia (Ho et al. 2011, Matsumoto et al. 2011).  HPV posi-
tivity for any hrHPV types on at least two occasions within a minimum of six 
months increases the risk of developing lesions compared to repeated negative test 
(Liaw et al. 1999, Kjaer et al. 2002, Ho et al. 2004, Auvinen et al. 2007, Syrjänen et 
al. 2009b). The risk appears to be higher for single type-specific persistence than 
persistence of multiple hrHPV types (Kjaer et al. 2002, Luovanto et al. 2010a) but 
the differences in PCR sensitivity have not been fully accounted for. HPV16 domi-
nates persistent infections followed by HPV types 18, 31, 33 and 45. The risk factors 
affecting the likelihood of HPV persistence are: pre-existing HPV infection, multi-
ple HPV infections, HIV status, smoking, age and genetical factors (Tam et al. 2010, 
Banura et al. 2010, Luovanto et al. 2011b). The period of persistence is associated 
with the production of low virion copy numbers, disruption of the maturation of the 
epithelium and abnormal cellular changes (Schiffman et al. 2005). The progression 
rate to squamous intraepithelial lesion (SIL) ranges between 20% and >70%. About 
70% of LSILs regress spontaneously, while about 6% of LSIL progress to HSIL or 
worse. In about 10% to 20% of women with HSIL the lesion progresses to ICC 
(Campion et al. 1986, Bosch et al. 2008) in a period of 20 years (Figure 3). However, 
there are cases of aggressive carcinomas mainly caused by persistent HPV18 that 
may occur in young women (Ostör 1993).  
 
 
 
Figure 3. Natural history of persistent HPV infections and disease progression. 
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The morphological changes of the persistently hrHPV infected cell are characterized 
microscopically and graded from normal cytology to ICC according to the severity 
of tissue damage (Figure 3).  Different systems use different terminologies (Solo-
mon et al. 2002)  for the precancerous abnormalities as summarized below (Table1).  
Table 1. Terminologies used to describe cervical precancerous abnormalities by different 
systems 
 
Pap 
classification 
 
1 
 
2 
 
3 
 
4 
 
5 
Dysplasia Normal Inflammation, 
metaplasia 
Mild , 
Moderate, 
severe 
Carcinoma 
in situ 
ICC 
CIN Normal -Inflammation 
-metaplasia 
cellular atypia 
CIN1, 
CIN2, 
CIN3 
CIN3 ICC 
Bethesda -Negative 
for malignancy 
- reactive 
cellular 
changes 
and infections 
ASC 
or ASCUS 
LSIL or 
HSIL 
HSIL ICC 
 
The terminologies used above can be summarized as follows: Dysplasia or Neopla-
sia indicate a change in the cells on the surface of the cervix. They do not necessar-
ily signal cancer, but a repeat Pap test is necessary. Atypical Squamous Cells of 
Undetermined Significance (ASCUS) indicates mild cellular changes, which makes 
it difficult to distinguish between benign tissue and neoplasia, a repeat Pap test in 6 
to 12 months is recommended. Low-Grade Squamous Intraepithelial Lesion (LSIL): 
indicates potentially precancerous change, follow-up with either a Pap test in 6 to 12 
months or colposcopy is necessary. High-Grade Squamous Intraepithelial Lesions 
(HSIL), also known as moderate or severe dysplasia or carcinoma in situ (CIS), 
requires surgical treatment to remove the lesions if the severity is confirmed by bi-
opsy. Squamous cell carcinoma: a cancerous lesion requires treatment by radical 
hysterectomy, radiation therapy and chemotherapy.  
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2.5.4 Cofactors of persistent HPV infections 
Young women involved in risky taking sexual behaviour from an early age onwards, 
exposes them to several sexual partners who are likely to be HPV infected (Burchell 
et al. 2006, Wellings et al. 2006, Luovanto et al. 2011a). This increases the risk be-
cause young women have a large cervical transformation zone (TZ) which makes 
them more susceptible to acquiring cervical HPV infections than older women. 
Similar observations have been made for HIV acquisition among adolescent women 
(Moss et al. 1991). Moreover, inadequate immune response/poor virus clearance at a 
young age may increase susceptibility to the acquisition and persistence of viral 
infections (Cuschieri et al. 2004, Moscicki et al. 2001, Malik et al. 2009, Banura et 
al. 2010).  
 
Prolonged use of contraceptives has been associated with increased risk of HPV 
acquisition (Smith et al. 2003, Nielsen et al. 2009, Kaushic et al. 2011). Oral contra-
ceptives are known to promote cervical ectopy and to increase susceptibility to HPV 
acquisition, also after adjusting for smoking and risky taking sexual behaviour 
(Winer et al. 2003). A recent article by Kaushic et al. (2011) suggests that changes 
in the microenvironment of the female tract due to hormonal, progestrogen based 
contraceptives especially increase the risk of acquiring STIs. These biological phe-
nomena are highly relevant since contraceptive use is associated with unprotected 
sex, often with several partners. 
 
Host genetic factors have been reported to be associated with the establishment of 
persistent HPV infections and the development of CIN (Segat et al. 2009, Castro et 
al. 2009). But a lot is still unknown about genetic susceptibility to HPV infections 
and their sequelae. Furthermore, it is not clear if genetics is associated with all HPV 
infected people not seroconverting. In other persistent viral infections, genetics does 
not seem to be associated with antibody response, even if specific immune genes 
(e.g. IL-10) are associated with their severity and reactivation (Kuparinen et al. 2011, 
Hurme et al. 2003). More research on the genetic determinants of HPV infections is 
needed.  
 
Impaired cellular immunity is associated with increased incidence and prevalence 
of multiple HPV infections reported in renal transplant patients and HIV positive 
individuals (Viscidi et al. 2004, Banura et al. 2008a, Banura et al. 2010). CD4 T 
helper cells are known to play a role in the control of HPV at the mucosae, hence 
HIV depleted T helper cells give more room for the establishment of HPV infection 
(Clifford et al. 2006). Even after the introduction of anti-retroviral therapy, the 
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prevalence and incidence. i.e., acquisition, of multiple HPV infections remains high 
in the HIV infected although cervical lesions regress (Palefsky et al. 2009).  
 
Other sexually transmitted infections with Chlamydia trachomatis, and herpes 
simplex virus 2 (HSV-2) are known to cause mucosal inflammation and immune 
suppression, which facilitates the establishment of HPV infections. C.trachomatis 
may also be an indepent co-factor of CIN3 development (Lehtinen et al. 2011). 
Some studies also suggest that HPV increases the risk of HIV infection (Smith-
McCune et al. 2010, Auvert et al. 2010). On the other hand, the associations of dif-
ferent STI occurrences may be all due to risky taking sexual behaviour, and the na-
ture/mechanisms of possible interactions between any two given STIs are unclear 
(Herfs et al. 2010).  
 
Smoking, the association between smoking and HPV carcinogenesis has been estab-
lished in a number of studies (Szarewski et al. 1996, Plummer et al. 2003, Simen-
Kapeu et al. 2009). Smoking impairs antibody response to genital HPV infections 
(Simen-Kapeu et al. 2008). While HPV IgG antibodies protect against incident HPV 
infection and its progression to CIN (Malik et al. 2009), impaired IgG antibody re-
sponse has been suggested to increase the risk of reinfection and persistence of the 
virus (Ho et al. 1995, Carter et al. 2000, Viscidi et al. 2004).  Immunosuppressive 
effects of smoking on both innate and adaptive immunity have been described 
(Sopori et al. 2002).  
2.6 Cervical Cancer 
Cervical cancer is the third most common incident cancer among women worldwide 
(Ferlay et al. 2010, Arbyn et al. 2011) with an overall age-standardised incidence 
rate (ASR) of 15.3 per 100,000 women albeit with a wide range of 0.4 to 56.3 (Fig-
ure 4) (Globocan 2008, Parkin et al. 2010, Arbyn et al. 2011). Globocan 2008 
(Global Cancer Statistics), showed that out of the 180 countries included in the pro-
gramme, CC ranks first in 42 countries (Globocan 2008 Arbyn et al. 2011). In 2008, 
there were 530,232 new CC cases and 275,008 deaths due to CC (Globocan 2008, 
Feray et al. 2008). The majority of new cases, 453,531 (85.5%) and 242,077 (88.0%) 
deaths due to CC occur in developing countries (Lehtinen et al. 2006, Sankaranara-
yanan et al. 2006, Jamel et al. 2011, Arbyn et al. 2011).  
 
Before the introduction of organised population based screening programmes the 
incidence of CC in the developed countries of Europe, North America and Australia, 
was as high as the current situation in the developing countries especially Sub Saha-
ran Africa. Following the implementations of these programmes the incidences have 
been low and the survival rates are quite high in developed countries, especially 
Nordic countries and North America (Bergstron et al. 1999, Anttila et al. 1999, 
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Smith et al. 2000, Petterson et al. 2011, Arbyn et al. 2011) and some parts of Asia 
(Sankaranarayanan et al. 2008). In other parts of the world devoid of screening pro-
grammes the incidence of and mortality from CC are increasing, for instance, in East 
and Central Africa, Central and Southern America, South-Central Asia, and Melane-
sia (Arbyn et al. 2011). In the last 10-15 years, however, some European countries 
have reported increasing incidences of cervical cancer in fertile-aged women (Ant-
tila et al. 1999, Arbyn et al. 2011).  
 
Figure 4. Global view of the age-standardized incidence rates (ASIRs) of cervical 
cancer within each country as estimated by GLOBOCAN 2008. (In the legend, the 
numbers in parentheses indicate the number of countries in each range of ASIRs). 
 
 
 
Figure 4. (Source: Prev Med 2011; 53 Suppl 1:S12-21)  
 
2.6.1 Burden of CC in developed countries (Finland) 
Following the introduction of cervical screening, CC incidence and mortality rates 
significantly declined by 80% in developed countries (IARC 2005). This is due to 
organised cytological screening programmes (Anttila et al.1999, Anttila et al. 2000, 
IARC 2005, Lazcano-Ponce et al. 2008, van der Aa et al. 2008, Pettersson et al. 
Uganda 
Finland 
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2011). In 2008, the number of new cases was 54,517, 5,213 and 151 for Europe, 
Northern Europe and Finland, respectively and 24,874, 2,141, and 63 deaths respec-
tively. The highest overall ASRs (14.5 per 100,000 women) are found in Eastern 
Europe and the lowest ASRs (6 per 100,000 women) in Western Europe. In recent 
decades the incidence of CC has, however, increased in a number of European coun-
tries: Sweden (1960s), Iceland (1980s), Finland, UK, Slovenia (1990s), and Bulgaria, 
Romania, Lithuania, Latvia (2000s) (Sigurdsson 1994, Bergström et al. 1999, Ant-
tila et al. 1999, Arbyn et al. 2011, Ferlay et al. 2011). The increase of CC incidence 
in fertile aged women has been due to low attendance of young women for cytologi-
cal screening (Finnish Cancer Registry 2010). A similar increase was also observed 
in the UK among women born before 1996 and aged 20-29 years of age (Foley et al. 
2011). The major factors for this increase were adoption of risky taking sexual be-
haviour followed by a specific increase of HPV16 infection incidence (Laukkanen et 
al. 2003, Nikula et al. 2007). 
 
Furthermore, despite the early success in reducing squamous carcinomas (SCC) in 
the developed world, especially in the Nordic countries (Figure 5), the incidence of 
adenocarcinomas (AC) is on the increase (Bray et al. 2005, Bulk et al. 2005, Petters-
son et al. 2011).   
 
2.6.2 Burden of CC in Africa (Uganda)  
 
In Sub-Saharan Africa, cervical cancer accounts for 22.2% of all cancers in women 
and is the leading cause of cancer death in women (Parkin et al. 2003). About 60-
75% of women in Sub-Saharan Africa who develop CC live in the rural areas and 
mortality is very high not only due to lack of access (financial and geographical) to 
health facilities but also to lack of knowledge of the disease both among health care 
workers and the female population (Parkin et al., 2002, Mutyaba et al. 2006, 2007, 
Urasa and Darj 2011). According to Globocan 2008, in the Sub-Saharan region, the 
highest ASR of CC is in East Africa (34.5 per 100,000 women), followed by West-
ern, Southern, and Middle Africa with 33.7, 26.8, and 23 per 100,000 women re-
spectively. By country Guinea has the highest and Egypt the lowest overall ASR and 
mortality rates of CC (Arbyn et al. 2011). 
 
Countries like Zimbabwe (Parkin et al. 1994) and Uganda (Wabinga et al. 2000, 
Parkin et al. 2003) have shown an increased incidence of CC over time, but no such 
increase has been observed in Nigeria and South Africa (Parkin et al. 2003). This 
increase may not be due to HIV, which is highly endemic in Eastern and Southern 
Africa as there have been no changes in the incidence of CC in Zimbabwe during 
the AIDS period (Parkin et al. 2003). Also in Uganda, the increase in the incidence 
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of CC began before the onset of the AIDS epidemic (Wabinga et al. 2000). Thus, the 
role of HIV on CC remains unknown. 
 
In Uganda, one of the countries with the highest age-standardized CC incidence 
(Parkin et al. 2005, Arbyn et al. 2011), it is estimated that 3,577 women are diag-
nosed and 2,464 women die from CC every year (www.who.int/hpvcenter/en/ Ac-
cessed 20 April 2011). The incidence rates of CC have tripled between the 1950s 
and the 2000s (Table 2). According to the Ugandan Cancer Registry, which was 
established in 1954, CC incidence has been increasing due to cases re-
ported/attending hospital following opportunistic screening. Perhaps the numbers 
will increase further if population based screening programme is set up. 
 
Table 2. Age-standardized incidence rates of cervical cancer in Uganda  
 
(Wabinga et al. 2000, Parkin et al. 2010) 
 
The age-specific incidence rates show an increase in CC by age from the 1950s. 
After the 1990s the peak is in menopausal women, followed by a plateau. This may 
be a birth cohort effect due to the social disruption during the wars of 1970 and the 
1980s which favoured the spread of STIs (Wabinga et al. 2000). The mean age at 
CC diagnosis is 43 years in all periods and the annual increase in ASR is 3% (Parkin 
et al. 2010). Screening of CC in Uganda is opportunistic and data on CC incidence 
in young age groups is lacking. The increase was assumed to be due to the HIV 
AIDS epidemic. In contrast to studies from developed countries reporting increased 
risk of CC among HIV positives (Biggar et al. 2007) studies in the East Africa, 
however, report marginal risk in HIV and others report no association between HIV 
and CC (Odida et al. 2011). On the other hand, African countries have reported a 
high risk of pre-neoplasia among HIV positives (La Ruche et al. 1998, Leroy et al. 
1999, Moodley et al. 2006).  
 
In Uganda the prevalence of HIV in general population is 6.5% (Todd et al. 2009). 
Among the HIV positives, 57% are women, and out of those women 76% are under 
30 years of age. HIV alone may not account for the high CC incidence and mortality 
in the country (Wabinga et al. 2000, Odida et al. 2011). Among the young women 
Period 1950s 1960-1966 1967-1971 1991-1995 1996-2001 2002-2006 
ASR  
per 100,000 
12.6 17.7 22.5 38.1 44.9 52.4 
 
 
THL — Research 80/2012 46 Occurrence of multiple HPV types among Finnish and Ugandan women 
 
(<30 years) risky taking sexual behaviour is on the increase. In addition, cross-
generation and polygamous marriages and child abuse have contributed to increased 
rates of HPV, HIV infections, and unwanted pregnancies, which are risk factors for 
cervical cancer (Parkin et al. 2002, Parkin et al. 2010). Thus the incidence of CC is 
likely to increase in Uganda.  
 
In contrast to a number of European countries, Uganda has no population-based 
cervical screening programmes and little is known about the causative agent and the 
disease among health care workers and women (Mutyaba et al. 2007). Therefore 
women seek medication mainly at the terminal stage of CC (Wabinga et al. 2003), 
and survival from CC is poor.  
 
2.7 HPV and Cancer 
2.7.1 History 
The link between cervical cancer and sexually transmitted infections was proposed 
by Domenico Antonio Rizoni-Stern in 1842. He noted that CC was less common 
among nuns than married women or widows (Rigoni-Stern 1842). Several studies 
later reported that the sexual behaviour of the male partner determines a woman’s 
risk for CC (Rotkin et al. 1973, Briton et al. 1989). Further work indicated that wid-
ows of men with penile cancer had increased mortality from CC (Smith et al. 1980) 
and that circumcision of the partner reduced the risk of developing the disease 
(Castellsague et al. 2002). All these studies indicated a sexually transmitted agent 
linked to CC. For nearly two decades most studies concentrated on the herpes sim-
plex virus type 2 (HSV-2) until a prospective study and lack of consistent findings 
on the virus from CC tissue refuted the suspicion in the middle of 1980’s (Vonka et 
al. 1984, Roizman et al. 1985). The causal association was flawed by residual con-
founding and homology between proliferating cell nuclear antigens and herpes virus 
proteins (Lehtinen et al. 2002).  
 
As early as in 1976 Harald zur Hausen hypothesized the causal relationship between 
CC and human papillomavirus, and in the early 1980s his research group in Heidel-
berg detected HPV16 and HPV18 in the CC tissues (zur Hausen et al. 1976, Durst et 
al. 1983, Schwarz et al. 1985). This opened the door to rapid development of HPV 
virology, and following the discovery of virus-like particles (Kirnbauer et al. 1992), 
to prophylactic vaccine development. 
 
Persistent infection with hrHPV types is the necessary cause of cervical cancer (Fig-
ure 5) (zur Hausen. 1996, Walboomers et al. 1999, Bosch et al. 2002, Munoz et al. 
2003, de Sanjose et al. 2010). The prevalence of hrHPV in cervical cancer cases 
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ranges between 89.9 and 99% (Clifford et al. 2006, Li et al. 2011) with hrHPV in-
fections accounting for 91% (de Sanjose et al. 2010).  There is an increase in the 
overall HPV infections from 85.6% to 92.9% and a reduction in single HPV infec-
tion from 82.1% to 76.8% in CC reported in studies published 1990-2010 (Li et al. 
2011) and during the same period an increase was also reported in the proportions of 
HPV16 from 51.8 to 60.0%. 
 
 
Figure 5. Natural history of HPV cervical cancer development  
  
 
 
2.7.2 HPV types related to CC  
Meta-analyses of studies on the occurrence of HPV types in CC published between 
1990 and 2010 showed that the predominant types in descending order are HPV16, 
18, 58, 33, 45, 31, 52, 35, 59, 39, 51 and 56 (Smith et al. 2007, Li et al. 2011). The 
same types were also observed in an IARC multicentrec cervical cancer study of 
3,085 invasive cervical cancer samples tested uniformly (Munoz et al. 2004), and in 
a large multi-centre study (Bosch et al. 2008). In all parts of the world HPV 16 is the 
most commonly identified type in CC tissues followed by HPV18. There are, how-
ever, geographical differences in the third position; HPV45 is the third most com-
mon type in Africa, North America, West/Central Asia, and Oceania, whereas 
HPV31 comes third in Europe and South/Central America, and HPV58 in Eastern 
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Asia (Li et al. 2011). Another study which analysed all the 22,661 paraffin-
embedded samples from 10,575 CC women from all over the world, reported the 
commonest hrHPV types to be HPV16, 18, 31, 33, 35, 45, 52 and 58 (de Sanjose et 
al. 2010). HPV16 alone was found in 60.6%, and HPV18 in 10.4% of CC cases. 
HPV16, 18, and 45 were found in 94% of cervical adenocarcinomas and have been 
associated with young age (de Sanjose et al. 2010). 
 
 
2.7.3 Multiple HPV infections and CC 
Several studies have shown an association between multiple persistent hrHPV infec-
tions and increased risk of CIN and CC (Cushieri et al. 2004, Herrero et al. 2005, 
Trottier et al. 2006, Odida et al. 2008, Munagala et al. 2009, Chaturvedi et al. 2011, 
Pista et al. 2011, Odida et al. 2011). The proportion of infections with multiple HPV 
types in ICC ranges 4-40% (Bosch et al. 2002, Trottier et al. 2006, Munagala et al. 
2009, de Sanjose et al. 2010, Pista et al. 2011). In CIN2+ multiple infections with 
HPV16, 18, 31, 33 and 51 are more common than single hrHPV infections (Pista et 
al. 2011). A meta-analysis of studies published from 1990 to 2010 showed an in-
crease in the prevalence of multiple HPV infections from 4.0% to 15.7% (Smith et al. 
2007, de Sanjose et al. 2010, Li et al. 2011). Geographical differences in the occur-
rence of multiple HPV infections among squamous cervical cancers (SCC) were 
reported with the highest prevalence found in Africa (12.4%), America (9.4), Aus-
tralia (7.8), Asia (7.8%), and Europe (6.2) (Munoz et al. 2004, Clifford et al. 2003, 
2006, Smith et al. 2007, Li et al. 2011).  
 
Multiple hrHPV infections are associated with HPV viral persistence (Ho et al. 
1998, Banura et al. 2011,) faster progression to CIN (Bachtiary et al. 2002), and 
poor response to tumour treatment (Munagala et al. 2009). On the other hand, some 
studies have reported very low prevalence of multiple HPV infections associated 
with CIN3 lesions or ICC (van Door et al. 2001, Okolo et al. 2010, Odida et al. 
2011), and others have reported no difference in the severity of disease progression 
between single and multiple HPV infections (Bosch et al. 2002, Herrero et al. 2000).  
2.7.4 HPV seroepidemiology and cervical cancer  
Most meta-analyses report on HPV DNA based data in different parts of the world; 
however, with a high rate of acquisition and clearance of the virus, it is difficult to 
assess the total lifetime number of HPV types one is exposed to. This is feasible 
with HPV serology due to the stability of antibodies for more than five years. Eco-
logical studies correlating HPV DNA prevalence with CC risk should be interpreted 
with caution as in the case of Denmark and Greenland. It had been observed that, 
women in Greenland had a low HPV DNA prevalence but a higher risk of CC com-
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pared to those in Denmark. However, when HPV serology was done, it was proved 
that although women in Greenland had low levels of current infections detected, 
their cumulative HPV exposure (indicated by antibodies) was higher than among 
women in mainland Denmark (Nonnenmarcher et al. 1996). 
 
Several prospective studies have suggested that seropositivity for HPV16 increases 
the risk for future development of cervical cancer (Carter et al. 1996, Lehtinen et al. 
1996; Dillner et al. 1997, Björge et al. 1997, Dahlström et al. 2011). Some studies 
showed an association between seropositivity to HPV18 and 33 and invasive cervi-
cal cancer (Dillner et al. 1997, Wang et al. 1997). Others suggested that seropositiv-
ity to both HPV types 16 and 18 increases the risk for CC development (Dillner et al. 
1997). The risk disappears if individuals are seropositive for both HPV16 and HPV6 
(Luostarinen et al. 1999). The order of acquiring infections with different HPV types 
appears to be important, since only individuals seroconverted for HPV6 before 
HPV16 seroconversion had negligible risk of CIN3+ (Luostarinen et al. 2011). On 
the other hand, some studies suggested that HPV antibodies are protective against 
disease development (Lehtinen et al. 1993, Ho et al. 2002). In a follow-up study 
there was no risk of progression to CIN3+ among women who seroconverted com-
pared to non-seroconverters (Carter et al. 2000, Syrjänen et al. 2009a).  
 
Because of the high vaccine efficacy in HPV vaccine clinical trials WHO has rec-
ommended mass HPV vaccination in developing countries (Villa et al. 2006, Paa-
vonen et al. 2007, 2009). However, there are no HPV vaccine clinical data available 
from Sub-Saharan Africa. One study from an HIV cohort in the USA (Levin et al. 
2010) showed lower poorly induced antibodies among HIV infected compared to 
HIV negatives. HPV DNA data show type difference among HIV positive and HIV 
negative groups (Clifford et al. 2005) and geographical HPV type variation has been 
reported, whereby in East African countries HPV16 was second to HPV52 among 
women with normal cytology (de Sanjose et al. 2007, Bruni et al. 2011, Banura et al. 
2011). However, it is unclear how the HPV types may differ among the HIV posi-
tive and HIV negative groups. 
 
The reduced risk of developing cervical squamous intraepithelial lesions in women 
with a history of anogenital warts was first suggested by Evans et al. (1992) to be 
due to antagonism between HPV types. Since then antagonistic interaction has been 
confirmed in a longitudinal setting among women seropositive for both lrHPV6/11 
and hrHPV16 antibodies with no or very low risk of ICC (Luostarinen et al. 1999, 
Dahlström et al. 2011). In serial sample analysis the antagonistic interaction is found 
only if HPV6 infection precedes HPV16 infection (Lehtinen et al. 2011). Antagonis-
tic interactions were also detected for combinations of HPV16 and HPV18 and of 
HPV16 and HPV33 (Luostarinen et al. 1999).  
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The interaction between HPV types is pivotal in understanding HPV-induced car-
cinogenesis and  predicting the likely effects of different preventive measures. For 
instance, it is not known why CC incidence is high in Sub-Saharan Africa, where 
lrHPV6 is highly prevalent. Could there be other mechanisms that affect the estab-
lishment of persistent HPV16 infection since it is not very common in general popu-
lation (Bruni et al. 2010, Banura et al. 2011) but most common in the CC patients 
(Smith et al. 2007, Banura et al. 2011, Li et al. 2011, Odida et al. 2011) in this re-
gion? 
2.7.5 HPV and non-cervical anogenital cancers (Anal, penile, vulva) 
HPV has also been widely reported in non-cervical anogenital cancers, the inci-
dences of which are on the increase in the most developed regions, apart from penile 
cancer, which is common in Africa (de Sanjose et al. 2007). Current data indicate 
that hrHPV infection is associated with cancers (Table 3); 90%-93% of anal cancers, 
12%-63% of oropharyngeal cancers, 36%-40% of penile cancers, 40%-64% of vagi-
nal cancers, and 40%-51% of vulvar cancers (De Vuyst et al. 2009, Chaturvedi 
2010). The commonest HPV types responsible for these cancers are HPV16 and 
HPV18, and account for 93%, 91%, 88%, and 73% of anal, vulvar, vaginal and 
penile cancers respectively (Smith et al. 2004). HPV16 alone was found in 73.7% 
and 68.4%, of invasive anal cancer, and anal HSIL tissues, and HPV18 was 7.6% 
and 7.0% respectively (Brooke et al. 2009). 
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Table 3. Burden of HPV related cancers.  
 
site 
 
1Annual numbers 
of cases worldwide. 
 
 
1Proportion of 
cancers attributable 
to HPV infections 
 
 
2Proportion of 
HPV-positive 
cancers attributable 
to HPV16/18 
 Total women   
Anus 27, 360 - 28,272 14,310 - 14,787 90-93 93 
Oropharynx 6,252 - 32,823 1,152 - 6,048 12-63 89-95 
Penis 9,468 - 10,520 NA 36-40 63-87 
Vagina 16,000 - 25,600 16,000 - 25,600 40-64 80-88 
Vulva 16,000 - 25,600 16,000 - 25,600 40-51 80-86 
Cervix 492,800 492,800 100 70-76 
Adapted from Chaturvedi (2010) J Adolesc Health. 46:S20-6. 1Gillison et al. 2008, Parkin and Bray 
2006,  2Gillison et al. 2008 
2.8 Prophylactic HPV Vaccine  
 
The primary mechanism of action for prophylactic viral vaccines is induction of 
humoral response (Breitburd et al. 1995). There are two licenced prophylactic HPV 
vaccines Cervarix™ (HPV16/18) and Gardasil™ (HPV6/11/16/18). These vaccines 
consist of virus-like particles (VLPs) that are produced by expressing the L1 gene of 
HPV 6/11/16/18 in yeast and of HPV16/18 in insect cells. The VLPs were highly 
immunogenic in the phase II studies (Villa et al. 2005, Harper et al. 2004). Alumi-
num derivatives in the adjuvant enhance the immune response. The HPV 6/11/16/18 
vaccine contains aluminiumhydroxy-diphoshosulphate, and the HPV-16/18 vaccine 
formulated with the AS04 Adjuvant System, comprises aluminium hydroxside sup-
plemented with the monophosphoryl lipid AS04. The monophosphoryl lipid AS04 
vaccine further increases the production of antibodies and specific memory B cells 
compared to the aluminum hydroxide adjuvanted vaccine (Giannini et al. 2006, 
Garcon et al. 2011). 
  
Following vaccination a robust antibody production takes place and memory B cells 
are induced to maintain circulating antibody levels. Most importantly, memory B 
cells help the immune system to swiftly generate high levels of antibodies when 
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challenged. Unlike other common viruses, HPV infections are local; being in the 
mucosa the virus tends to evade the immune system. Therefore generation of neu-
tralizing antibodies is important to restrict the infection within the host and transmis-
sion from the host (Stanley 2010a). Even though vaccine-induced HPV antibody 
levels are very high in all ages, HPV immune responses are age-dependent, the age 
group below 15 years showing the highest levels (Perez et al. 2008, Petäjä et al. 
2009, 2010). Factors such as smoking do not affect the vaccine-induced antibody 
levels (Kapeu et al. 2009). The effect of HIV on the HPV vaccine response is still 
unclear.  High and sustained antibody responses have been observed up to 10 years 
after vaccination for both HPV16 and 18 with the bivalent vaccine and for at least 
8.5 years with the quadrivalent vaccine (Harper et al. 2008, Frazer 2010).  
 
Although cross-protection against other HPV types has been demonstrated following 
HPV vaccination, the correlates and duration of protection are still unclear (Garcon 
et al. 2011, Wheeler et al. 2009, 2012). The vaccine efficacy against CIN3 asso-
ciated with any HPV type is more than 93% among baseline HPV naïve women 
(Lehtinen et al. 2012).  Efficacy was about 45% including women with baseline 
HPV infections (Lehtinen et al. 2012). Despite the promising HPV vaccine results 
from developed countries, HPV vaccine data is still unavailable from developing 
countries. A pilot study that evaluated the feasibility of HPV vaccine introduction, 
conducted in India, Peru, Uganda and Vietnam by PATH, (PATH 2010). Although, 
WHO recommends mass HPV vaccination basing on the results from developed 
countries, developing countries may consider implementing it only provided that 
resources are secured like in Rwanda the pioneering African country to implement 
mass HPV vaccination (Lancet 2011). Such programmes are of great importance if 
sustained. However, for such a big national health investment, effectiveness/impact 
data is required to help in planning for the best implementation strategies. Due to 
differences in environmental factors, there is an urgent need also for clinical trials to 
evaluate the effect of factors such as HIV, malaria, helminths infections which are 
endemic in Sub-Saharan countries on the immunogenicity and efficacy of the HPV 
vaccine.   
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3 AIMS 
 
 
The aim of this study was to use HPV antibodies as markers of cumulative HPV 
exposure (cumulative incidence) to study the occurrence of multiple HPV serotypes 
and to assess associated risk factors among Finnish and Ugandan women. 
 
The specific aims were: 
 
1. To determine the distribution of HPV seroprevalence and the occurrence of 
multiple HPV types among Finnish and Ugandan women  
2. To evaluate risk factors of seropositivity for multiple HPV types among 
Ugandan women  
3. To determine the risk of seroconversion to multiple HPV types among Fin-
nish women  
4. To evaluate the role of HPV16 antibody avidity in the acquisition of multi-
ple HPV types.  
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4 MATERIALS AND METHODS 
 
 
4.1 Study sites and cohorts 
The study participants were from two geographically different sites; Finland in 
Northern Europe and Uganda in East Africa. 
 
4.1.1 Finnish Maternity Cohort (FMC) 
The Finnish Maternity Cohort (FMC) is one of the largest serum biobanks in the 
world with more than 1.8 million serum samples collected from about 760,000 preg-
nant women in their first trimester (gestation period 8-12 weeks). The FMC biobank 
was established in 1983 with the aim of screening for congenital infections, and 
currently screens for HIV, hepatitis B virus and Treponema pallidum infections 
(Koskela et al. 2000). Since 2001, all women consent for their samples to be used in 
health related research performed by the National Institute for Health & Welfare 
(THL). For the samples collected before 2001 a law was passed by the Parliament of 
Finland for their use in the above context (Pukkala et al. 2007).  
At the THL Oulu laboratories all serum samples for screening obtained from the 
municipal antenatal clinics are processed and stored at -250C. The FMC covers more 
than 98% of all Finnish pregnant women. With appropriate ethics review board 
permissions, exposure data obtained from laboratory analyses of these samples can 
be linked to other registries (such as the Finnish Cancer Registry and available 
demographic and maternity data) by using the Finnish unique personal identity 
number (PID).  
 
4.1.2 Kuopio Cohort (KC) 
Kuopio is the capital of Eastern Finland. The KC was established from 1981 to 1998 
at the University of Eastern Finland (formerlUniversity of Kuopio) Hospital. Par-
ticipants were 532 women with   koilocytotic cells with or without dyskaryotic ab-
normal?Pap test from the routine cervical cancer-screening programme. A compre-
hensive gynaecological examination including repeated Pap test, colposcopy and a 
directed punch biopsy were done at recruitment and a questionnaire completed for 
other risk factors.  Blood samples were taken at six-month intervals for up to 10 
years (Kataja et al. 1992; Syrjänen et al. 1985).  
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4.1.3 Ugandan pregnant women 
A cross-sectional study was conducted among pregnant women attending antenatal 
clinics in three hospitals in central Uganda: Naguru Teenage Health and Information 
Center, Entebbe and Nsambya Hospitals. Entebbe Hospital is a district referral hos-
pital in a semi-urban setting about 40 km from Kampala (the capital city). It serves 
women within a distance of about 80 km including the islands in Lake Victoria. 
Nsambya Hospital is a tertiary, private (nonprofit) referral hospital in the suburbs of 
Kampala. It serves women of all income levels in private and public clinics within a 
distance of about 40 km. Naguru Teenage Health and Information Center is a mu-
nicipal health centre, about 5 km from Kampala city centre, Uganda, it serves 
women from nearby suburbs and especially teenage mothers.  
In Uganda all pregnant women are recommended to visit antenatal clinics for preg-
nancy related examination and for congenital screening of HIV and Treponema 
pallidum and to be vaccinated against tetanus. During the antenatal visit health talks 
are conducted, HIV pre-counselling in small groups (5 women) is offered, demo-
graphic data is collected, blood samples are donated to the laboratory and HIV post-
counselling per individual on delivery of blood test results. HIV and syphilis results 
are released on the same day and those positive for syphilis are treated and HIV 
positives are referred to other units for management (Mpairwe et al. 2003, Banura et 
al. 2008a, 2010).  
 
We conducted our study in collaboration with the Prevention of Mother to Child 
HIV Transmission Programme in antenatal clinics. The first group comprised 
women who participated in a follow-up study of young primiparous pregnant 
women at the Naguru Teenage Health and Information Center (Banura et al. 2008b) 
between May and November 2004. The second group of pregnant women was en-
rolled between October and December 2008 at the Entebbe and Nsambya hospitals 
during their first antenatal visit. Information about HPV was included in the routine 
health information given by trained midwives and nurses to pregnant women. A 
questionnaire to collect risk factors for HPV infections was completed after women 
consented in writing to participate in an STI serology study. 
 
4.1.4 Ethical clearance 
Ethical approvals for the respective studies were obtained from the ethics review 
boards at the National Institute for Health and Welfare, Finland; Uganda Virus Re-
search Institute, Entebbe, Uganda; St  Raphael of St Francis Hospital Nsambya, 
Kampala, Uganda and The Uganda National Council of Science and Technology. 
All women consented individually to participate in the STI serology study. 
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4.2 Study populations and data collected 
The following describe the four studies conducted as part of this thesis, which are 
subcohort of the above-mentioned cohorts. 
Paper I 
A cross-sectional study was conducted among the Finnish and Ugandan pregnant 
women as follows: A stratified random sub-cohort of 3,251 Finnish pregnant women 
with a mean age of 22 years (range 14-28 years, standard deviation (SD 3) who do-
nated serum samples between 1995 and 2003 was selected from the FMC (Kaasila et 
al. 2009). A total of 2,053 Ugandan pregnant women with a mean age of 23 years 
(range 14-48 years, SD 5) were enrolled. Altogether 471 Finnish and 69 Ugandan 
women were excluded due to inadequate volume of serum sample. A total of 2,780 
Finnish and 1,984 Ugandan women were included in the HPV antibody analysis 
against 7 HPV types 6/11/16/18/31/33/45 using VLP-based ELISA.  
 
Paper II 
Out of the 1,984 serum samples used in Paper I from the Ugandan pregnant women,  
all 1,943 serum samples with adequate volume were analysed for antibodies to eight 
oncogenic HPV types (16/18/31/33/35/45/52/58) using multiplex serology assay at 
the German Cancer Research Center (DKFZ) in Germany. 
 
Paper III  
Four hundred and eighty (480) women from the Kuopio cohort with abnormal Pap 
tests were followed up at 6-month intervals for an average of 60.3 months (Kataja et 
al. 1992; Syrjänen et al. 1985, Simen-Kapeu et al. 2008), but only 437 women had at 
least two serum samples and were included in this HPV seroconversion study. Anti-
bodies to seven HPV types 6/11/16/18/31/33/45 were analysed using VLP-based 
ELISA. 
 
Paper IV 
Three hundred and sixty five (365) pregnant women (both Finnish and Ugandan) 
were selected by simple random method from 994 HPV16 antibody-positive women 
identified from Paper I and included in a study on HPV16 antibody avidity with a 
modified VLP-based ELISA.    
4.3 Laboratory analysis 
4.3.1  Measuring HPV antibodies using VLP-based ELISA (Papers I and III) 
Serum IgG antibodies against seven specific HPV types 6/11/16/18/31/33/45 were 
analysed using virus-like particle (VLP) based Enzyme-linked Immunosorbent As-
say (ELISA) as described previously (Dillner et al. 1996, Dessy et al. 2008, Kaasila 
et al. 2009). VLPs were generously donated by Dr. Kathrin Jansen (HPV6/11/16, 
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Merck Research Laboratories, Philadelphia, PA, USA), Dr. Reinhard Kirnabauer, 
University of Vienna, Austria (HPV types 31/33) and Dr. Francis Dessy (HPV types 
18/33/45, GlaxoSmithKline Biologicals, Rixensart, Belgium). Sera and controls 
were diluted 1:30 in assay diluents. Fifty µl of the diluted samples were added in 
singlicates on the 96-well plate. Assay drift was monitored by adding blank (assay 
diluent), negative, positive and low-positive (1:100) controls in duplicate per plate. 
The negative control was serum samples pooled from adolescent virgins as indicated 
in previous work (Dillner et al. 1996, Lehtinen et al. 2006, Simen-Kapeu et al. 2008), 
and later a new negative control, a pool of sera seronegative for all the seven HPV 
types 6/11/16/18/31/33/45 was applied. The positive controls were pooled from 
samples seropositive for all seven types.  
4.3.2 Multiplex serology (Paper II) 
We analysed the Ugandan sera to include other HPV types commonly reported in Africa. 
Antibodies against eight different oncogenic HPV types were analysed simultaneously 
(Waterboer et al. 2005).  Briefly, bead sets (3,000 beads per set per well) carrying dif-
ferent antigens were mixed. Equal volumes of diluted serum and mixed beads were 
mixed into 96-well plates. The beads were washed off after one hour’s incubation at 
room temperature. Secondary antibody and conjugate were added, with incubation and 
washing steps in between. Reporter fluorescence of the beads was determined with a 
Luminex analyser and expressed as median fluorescence intensity (MFI) of at least 100 
beads per set per well. Cut-offs for seropositivity of specific hrHPV types 
16/18/31/33/35/45/52/58 were 422, 394, 712, 515, 552, 368, 547, 592 MFI respectively 
(Dondog et al. 2008). 
4.3.3 Modified ELISA for HPV16 IgG antibody avidity measurements 
(Paper IV) 
The procedures for HPV VLP-based ELISA were followed with modifications. First 
we optimized for the molarity of urea between the ranges of 4M to 8M and the best 
curve was obtained with 6M of urea (unpublished). For the rest of the sample analy-
sis we used 6M urea. Serum samples were serially diluted: 1:1, 1:4, 1:16, 1:64, 
1:256 in phosphate-buffered saline (PBS) with 10% fetal bovine serum (blocking 
buffer, BB). Fifty µl of diluted samples were added to wells A-D (1:4, 1:16, 1:64, 
1:256) and wells E-H (1:1, 1:4, 1:16, 1:64). Blank (assay diluent), low- and high-
avidity controls were added to columns 1, 2 and 3, and incubated overnight at 4oC. 
Wells A-D were washed three times with 200µl of PBS/0.05% Tween 20 (PBS+T), 
and wells E-H were washed with 6M urea after we optimized for assay. (Promega, 
Biofellows, Finland) in PBS. Each wash was for 5 min. Avidity index (AI) and cut-
off of low avidity were calculated as described previously (Hedman et al. 1989, 
Herne et al. 1997, Namujju et al. 2011).  
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4.3.4 Other serology measurements (Papers I-IV) 
HIV-serology 
In Uganda, a serial testing algorithm was applied to detect HIV antibodies: All se-
rum samples were screened using the Abbott rapid kit (Abbott Laboratories, Abbott 
Park, IL, USA) and positive samples were re-analysed on Unigold rapid kit (Unigold 
Trinity Biotech PLC, Bray, Ireland) and in case of discordant samples a tie breaker, 
Murex HIV-1.2.0 ELISA (Murex Biotech, Ltd.,Dartford, UK) was used to confirm 
the results, (Mpairwe et al. 2005, Banura et al. 2008). All Ugandan samples were re-
analyzed in Oulu, Finland, using the Abbott Combo test (Abbott Ireland, Diagnostic 
Division, Sligo, Ireland). The Finnish samples were analyzed with the Abbott 
Combo test. 
 
 
Chlamydia trachomatis serology  
IgG antibodies to C. trachomatis were analysed using a commercial kit (Anilabsystems, 
Helsinki, Finland) as described (Dillner et al. 1996). 
 
Cotinine  
Cotinine is a metabolite (byproduct) of nicotine as it is processed by the human body. 
It is a biomarker for nicotine exposure. Cotinine measurement was done using a 
commercial qualitative immunoassay (OraSure Technologies, Bethlehem, Pennsyl-
vania) following the manufacturer’s instructions. Results above the cut-off level 
(>20ng/mL) indicated a current smoker (Simen-Kapeu et al. 2008) 
 
4.4 Statistical methods 
Statistical analyses for Papers I, II, & IV were carried out using Stata 8 (Stata Corp., 
College Station, Texas, USA) and for Paper III SPSS16.0 for Windows was used 
(SPSS Inc., Chicago, IL, USA). Two-sided p<0.05 was considered to be statistically 
significant. Descriptive statistics such as mean, standard deviations and proportions 
were calculated for the variables.  
A logistic regression model was used to calculate the relative risk (RR), estimated as 
crude and adjusted odds ratios (OR) with 95% confidence interval (CI) for seroposi-
tivity to multiple HPV types. We defined overall seropositivity as antibody positiv-
ity to at least one of the HPV types analysed in that study, and multiple HPV types 
as positivity to at least two of the HPV types analysed. 
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Paper I 
Being seropositive for multiple HPV types was the main outcome measurement. 
Univariate logistic regression was used to estimate the relative risk (OR) with 95% 
CI of being seropositive for at least two HPV types among seropositive women for a 
specific type as compared to seronegative women for that particular type. Adjust-
ments were made for age, smoking and HIV.  
 
Paper II  
The main outcome measurement was seropositivity for multiple hrHPV types. The 
univariate, logistic regression model was used to estimate the relative risk (OR) with 
95% CI of being seropositive for multiple hrHPV types among Ugandan pregnant 
women according to different variables (age, age at sexual debut, number of lifetime 
sexual partners, parity, education, smoking, HIV, and C. trachomatis ). Multivariate 
and stepwise (eliminating one variable at a time) multivariate logistic regression 
models were used to assess the independent and stand-alone independent risk factors 
respectively. We also estimated the risk (OR) with 95% CI of being seropositive for 
multiple HPV types among women seropositive for HPV16 or HPV18 as compared 
to seronegative women for that particular type by HIV status. We further estimated 
the risk of being seropositive for double HPV types among seropositive women for a 
specific HPV type compared to seronegative women for that particular type by HIV 
status. Adjustment was made for age and C. trachomatis seropositivity. 
 
Paper III 
The proportions of seroconversions were calculated among women who were anti-
body negative for a specific HPV type at baseline but seropositive for that particular 
HPV type at the follow-up sample. We used the univariate logistic regression model 
to estimate the relative risk (OR) with 95% CI of seroconversion for another HPV 
type among baseline seropositive women for a specific HPV type compared to sero-
negative women for that particular type. We further stratified the HPV types as low-
risk (lr) or high-risk (hr), and estimated the RR with 95% CI of seroconversion to 
hrHPV types among lrHPV seropositives as compared to seronegatives.  
 
Paper IV 
As HPV16 is one of the most common hrHPV types, we assessed the association 
(OR with 95% CI) of low-avidity HPV16 antibodies with seropositivity for multiple 
HPV types compared to being seropositive for HPV16 only among HPV16 seroposi-
tive women using the univariate model. Adjustment was made for age, C. trachoma-
tis and HIV seropositivity, and smoking. 
 
 
THL — Research 80/2012 60 Occurrence of multiple HPV types among Finnish and Ugandan women 
 
5 RESULTS 
 
Paper I -Occurrence of seropositivity to multiple HPV types among Finnish    
and Ugandan women  
The seroprevalences of specific HPV types, HIV and C. trachomatis antibodies, and 
smoking among both Finnish and Ugandan pregnant women are summarized below 
for Papers I, II and III (Table 4). 
Table 4.  A summary of HPV seroprevalence (%) based on HPV VLP ELISA and 
multiplex HPV serology measurements, and other STIs among Finnish and Ugandan 
women in Papers I, II, III. 
 VLP-based ELISA Multiplex serology 
  
Pregnant women  
(Paper I) 
Kuopio 
–Finnish women with 
abnormal Pap tests 
(Paper III) 
Ugandan  
pregnant women 
(N=1943) (Paper II) 
 Finnish 
women 
(FMC) 
(N=2784) 
Ugandan 
women 
(N=1964) 
Baseline 
sample 
(N=437) 
Follow-up 
sample 
sero-
prevalence 
Among 
HIV+ 
Among 
HIV- 
HPV6 12 30 33 32 na na na 
HPV11 11 26 20 18 na na na 
HPV16 21 21 21 19 15 22 14* 
HPV18 14 8 11 10 16 17 16 
HPV31 12 16 15 12 13 12 13 
HPV33 11 23 16 15 9 11 9 
HPV35 na na na na 7 4 7 
HPV45 5 11 27 31 13 19 12* 
HPV52 na na na na 8 16 8* 
HPV58 na na na na 5 3 5 
C. trachomatis 25 27 28 30 27   
HIV 0 7 na na 7   
 26 3 36 35 3   
   * Types significantly different by HIV status in Paper II only, na= not applicable 
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Seroprevalence  
 
The overall seroprevalence (for at least one) and for multiple HPV types (at least 
two) of the HPV types 6/11/16/18/31/33/45) were low among Finnish (44% (1,222) 
and 22% (619) respectively) compared to Ugandan women (57% (1 118) and 30% 
(588) respectively) (p <0.001). For the Finnish women, age-specific overall HPV 
seroprevalence peaked in the age-group 20-24 years, while the seropositivity rate, i.e. 
seroprevalence for multiple HPV types increased with age up to the age group 25-29 
years. Whereas for the Ugandan women both prevalences peaked in < 20-year olds 
and declined thereafter with increasing age (Paper I).  Seropositivity for multiple 
HPV types among HPV positive women was common in both Finnish (51%) and 
Ugandan (53%) women. In Finland 26%, 12% and 13% of the seropositive women 
had antibodies for two, three and four or more HPV types respectively, whereas in 
Uganda 30%, 12%, 9% had similar antibodies respectively. The HPV16 seropreva-
lences were similar in both countries (21%). Among the Finnish women seropositiv-
ity was most common for HPV types 16, 18, 31 and 33, whereas among the Ugan-
dan women the corresponding HPV types were 33, 16, 31 and 45 (Table 4).  
Ugandan HIV-positive women had higher HPV seroprevalences both overall (74%, 
104 of 140) and for multiple HPV types (53%, 74 of 140) than HIV-negative women 
(56%, 1,014 of 1,842 and 28% 514 of 1,824) for overall and multiple HPV types 
respectively. 
 
 
Risk of being seropositive for multiple HPV types 
  
Overall, seropositive women compared to women seronegative for any of the spe-
cific HPV types (6/11/16/18/31/33/45), had an increased risk of being seropositive 
for a second HPV type with the OR ranging between 1.8 and 12.2 among Finnish 
women and 1.7 to 5.3 for Ugandan women. Compared to Ugandan women (HPV45U) 
(lower left half in Table 5), Finnish women who were seropositive for HPV45 
(HPV45F) (upper right half in Table 5) had a significantly higher risk estimate of 
double seropositivity for HPV types 16, 18, 31 and 33. There was no significant 
differences for the phylogenetically related HPV31/33 between Finnish and Ugan-
dan women despite the increased risk estimates for double seropositivity among the 
HPV16 seropositives (Table 5). 
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Table 5. Odds ratios with 95% confidence intervals of being seropositive to another HPV 
type if seropositive to a defined HPV type among pregnant Finnish (upper righr half, 
n=2,780) or Ugandan (lower left half, n=1,964) women, with HPV-seronegative 
women as the reference group. 
Risk of double HPV antibody positivity  
 
HPV  
antibody 
status 
6/11 
OR(95%CI) 
16 
OR(95%CI) 
18 
OR(95%CI) 
31 
OR(95%CI) 
33 
OR(95%CI) 
45 
OR(95%CI) 
6/11       
Positive na 2.4 (1.6–3.7) 3.1 (1.9–4.9) 3.4 (1.9–5.8 2.2 (1.3–3.7) 1.8 (0.8–4.1) 
16       
Positive 1.9 (1.5–2.5) na 6.7 (4.3–10.5) 4.7 (2.8–7.9) 7.0 (4.3–11.4) 6.5 (3.2–13.3) 
18       
Positive 2.0 (1.3–3.0) 5.3 (3.8–7.5) na 5.2 (3.0–9.0) 6.9 (4.1–11.7) 10.9 (5.3–23) 
31       
Positive 2.2 (1.6–2.9) 3.8 (2.9–5.0) 3.1 (2.2–4.4) na 4.5 (2.5–8.2) 6.1 (2.8–13.4) 
33       
Positive 3.0 (2.3–3.8) 4.6 (3.6–5.8) 3.3 (2.3–4.6) 3.5 (2.7–4.5) na 12.2 (5.8–26) 
45       
Positive 1.7 (1.2–2.4) 2.0 (1.4–2.7) 3.4 (2.3–5.0) 2.2 (1.6–3.0) 3.3 (2.4–4.5) na 
Adjusted for age, smoking (Finland and Uganda) and HIV positivity (Uganda), A significant difference 
= when the confidence intervals of estimates for risk of double seropositivity of particular HPV types 
between the two populations do not overlap. 
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Paper II- Risk of seropositivity for multiple hrHPV types among Ugandan 
HIV-positive and HIV- negative women  
 
Determinants of seropositivity for multiple hrHPV types 
We observed that age (30 years and above) and education (tertiary level) had a pro-
tective effect against being seropositive for multiple HPV types. Conversely, age at 
sexual debut, number of sexual partners and smoking had no effect, but parity (>5), 
C.trachomatis and HIV antibody positivity increased the risk of being seropositive 
for multiple HPV types in a univariate model. Again, in the multivariate model all 
factors remained significant except that the risk associated with C.trachomatis sero-
positivity disappeared (Table 6). In the stepwise model (analysed by elimination of 
the variables one at a time), only HIV remained the stand-alone, independent risk 
factor for seropositivity to multiple hrHPV types. 
 
Risk of seropositivity for multiple hrHPV types by vaccine types 
 
We observed that women seropositive for vaccine type HPV16 or HPV18 compared 
to women seronegative for those particular types had an increased risk of being se-
ropositive for multiple hrHPV types. The differences, however, were not statistically 
significantly different by HIV status (HPV16/HIV+; OR 11.8, 95% CI 4.5-31.5 vs 
HPV16/HIV-; OR 21.8, 95%CI 15.4-30.8 and HPV18/HIV+; OR 58.1, 95% CI 
13.9-242 vs HPV18/HIV-; OR 44.8, 95% CI 31.1-64.7). Furthermore, although 
seropositivity for a specific hrHPV type compared to seronegativity increased the 
risk of being seropositive for another hrHPV type, no statistical differences were 
observed in the risk estimates between HIV-positive and HIV-negative women. 
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Table 6. Univariate and multivariate estimation of the relative risk (RR) of seropositivity for multiple 
high-risk human papillomavirus (HPV) types among pregnant Ugandan women (N=1,209)  
Characteristic  hrHPV antibody 
Univariate 
multiple hrHPV  
types RR (95% CI) 
Multivariate 
multiple hrHPV  
types RR (95%CI) 
 number (n) percentage positive (%)   
Age       
<20 150 12 % 38 (25) 1  
20-24 425 35 % 83 (20) 0.7 (0.5-1.1) 0.7 (0.4-1.1) 
25-29 385 32 % 86 (22) 0.8 (0.5-1.3) 0.8 (0.5-1.3) 
>=30 249 21 % 42 (17) 0.6 (0.4-1.0)* 0.5 (0.3-0.8)* 
Age at sexual debut       
<15 120 10 % 29 (24) 1  
15-20 903 75 % 185 (20) 0.8 (0.5-1.3) 1.0 (0.6-1.7) 
>20 186 15 % 35 (19) 0.7 (0.4-1.3) 1.1 (0.5-2.2) 
Life-time partners       
1 314 26 % 64 (20) 1  
2 377 31 % 76 (20) 1.0 (0.7-1.4) 1.1 (0.7-1.6) 
3 238 20 % 52 (22) 1.1 (0.7-1.6) 1.0 (0.6-1.6) 
>3 280 23 % 57 (20) 1.0 (0.7-1.5) 1.0 (0.6-1.6) 
Pregnancies       
<5 970 80 % 192 (20) 1  
>5 239 20 % 57 (24) 1.3 (0.9-1.8) 1.6 (1.0-2.5)* 
Educationa       
<=Primary 352 33 % 92 (26) 1  
Secondary 445 42 % 91 (20) 0.7 (0.5-1.0) 0.8 (0.6-1.2) 
Tertiary 266 25 % 43 (16) 0.5 (0.4-0.8)* 0.6 (0.4-1.0) 
Smokingb       
no 1 103 96 % 228 (21) 1  
yes 47 4 % 10 (21) 1.0(0.5-2.0) 0.9 (0.4-1.9) 
HIV       
negative 1 114 92 % 297 (27) 1  
positive 54 8 % 35 (37) 1.8 (1.1-2.8) * 1.7 (1.0-2.8)*,† 
Chlamydiac       
negative 875 73 % 164 (19) 1  
positive 322 27 % 81 (25) 1.5 (1.1-2.0) * 1.1 (0.8-1.6) 
* = statistically significant risk factor for multiple hrHPV seropositivity, † = statistically significant, independ-
ent risk factor for multiple hrHPV seropositivity an=1063, bn=1150, cn=1197   
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Comparison of Results from HPV VLP ELISA and multiplex serology assays 
for Ugandan women 
 
Antibodies against HPV 11/16/18/31/33/45 were analysed using two techniques: 
VLP based HPV ELISA (Paper I) and multiplex serology (Paper II) in two laborato-
ries, Oulu (Finland) and Heidelberg (Germany). The results showed observed 
agreement above 70% but the kappa values were very poor (Table 7).  
 
Table 7. Comparison between conventional HPV VLP based ELISA and Multiplex 
serology methods in the analysis of HPV IgG antibodies.  
HPV type 
Total number* 
n=1948 
Observed  
agreement  
(%) 
Expected  
agreement  
(%) 
kappa 
95%  
Confidence 
interval 
Z 
 
Positive 
on ELISA 
Positive 
on multiplex 
     
 
HPV11 
 
420 
 
344 
 
71.3 
 
58.4 
 
0.31 
 
0.26-0.37 
 
11.32 
 
HPV16 
 
406 
 
285 
 
77.4 
 
70.6 
 
0.23 
 
0.18-0.28 
 
10.35 
 
HPV18 
 
153 
 
316 
 
78.4 
 
78.4 
 
0.18 
 
0.12-0.23 
 
8.49 
 
HPV31 
 
304 
 
246 
 
75.7 
 
75.7 
 
0.18 
 
0.13-0.24 
 
8.01 
 
HPV33 
 
440 
 
184 
 
72.2 
 
72.2 
 
0.20 
 
0.15-0.25 
 
10.09 
 
HPV45 
 
205 
 
251 
 
79.3 
 
79.3 
 
0.11 
 
0.05-0.16 
 
4.76 
* = excludes HPV11 (n=1304) 
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Paper III - Risk of seroconversion to multiple HPV types in a follow-up study 
 
Proportions of seroconversion among baseline seropositives 
 
We observed no protection against seroconversion to another HPV type among 
baseline seropositive women. The proportions of seroconversions among women for 
at least one other HPV type (multiple HPV types) among baseline HPV seroposi-
tives to any of the HPV types 6, 11, 16, 18, 31, 33, and 45, were generally high, 
ranging from 73% to 98% as reported in the descending order among baseline sero-
positive women for hrHPV types: 98% (HPV18), 90% (HPV16), 78% (HPV45), 
77% (HPV33) and 73% (HPV31) and for the lrHPV types were 95% (HPV11) and 
93% (HPV6).   
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Risk of seroconversion among baseline HPV16 or HPV18 seropositives 
 
We observed that among the HPV16 or HPV18 baseline seropositive women the 
risk of seroconversion was statistically significantly increased for the phylogeneti-
cally related HPV types HPV31 and HPV33 (HPV16/HPV31: OR 2.5, 95CI 1.5-4.3; 
HPV16/HPV33: OR 3.4, 95%CI 2.0-5.8; HPV18/HPV31: OR 6.2, 95%CI 3.2-12.0; 
HPV18/HPV33: OR 8.6, 95%CI 4.2-17.0. On the other hand, the risk of seroconver-
sion to HPV18 among the baseline HPV16 seropositive women was 5.5 fold (95% 
CI 2.8-10.0) and for seroconversion to HPV16 among the HPV18 baseline seroposi-
tives was 7.4 fold (3.8-14) (Table 8).  
 
We further noted that when multiple types were stratified into low and high risk 
types, seropositivity to multiple lrHPV (6/11) types at baseline compared to sero-
negativity increased the risk of seroconversion to multiple hrHPV types 
(16/18/31/33/45) (OR 2.3, 95% CI 1.1-4.7). 
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Table 8. Risk of HPV seropositive compared to seronegative (reference group) women at 
baseline to seroconvert to another HPV type during follow-up study.  
 Risk of seronconversion 
First  
sample  
HPV  
antibody 
status 
6 
OR 
(95%CI) 
11 
OR 
(95%CI) 
16 
OR 
(95%CI) 
18 
OR 
(95%CI) 
31 
OR 
(95%CI) 
33 
OR 
(95%CI) 
45 
OR 
(95%CI) 
6        
Positive - 6.5 (3.9–11) 2.2 (1.3–3.6) 2.4 (1.3–3.5) 1.5 (0.9–2.5) 1.7 (1.1–2.7) 0.8 (0.5–1.4) 
11        
Positive 8.2 (4.7–14) - 2.6 (1.5–4.7) 1.8 (0.9–3.7) 2.6 (1.5–4.5) 2.7 (1.6–4.7) 0.8 (0.4–1.5) 
16        
Positive 2.4 (1.5–4.0) 2.0 (1.1–3.5) - 5.5 (2.8–10) 2.5 (1.5–4.3) 3.4 (2.0–5.8) 0.7 (0.4–1.3) 
18        
Positive 1.7 (0.9–3.3) 1.9 (0.9–3.9) 7.4 (3.8–14) - 6.2 (3.2–12) 8.6 (4.2–17) 1.4 (0.6–3.0) 
31        
Positive 1.1 (0.6–2.1) 1.0 (0.5–2.2) 0.8 (0.3–1.8) 0.7 (0.2–2.1) - 4.3 (2.3–7.9) 2.5 (1.4–4.4) 
33        
Positive 1.3 (0.7–2.4) 1.0 (0.5–2.1) 0.7 (0.3–1.6) 0.7 (0.3–2.1) 4.3 (2.2–8.2) - 5.9 (3.4–10) 
45        
Positive 0.8 (0.5–1.5) 1.2 (0.6–2.2) 0.9 (0.5–1.7) 0.9 (0.4–2.2) 2.7 (1.5–5.8) 4.9 (2.8–8.5) - 
Adjusted for Chlamydia trachomatis antibodies  
 
Paper IV- Association of low-avidity HPV16 antibodies and seropositivity for 
multiple HPV types  
The overall proportion of women with low avidity HPV16 antibodies was 18% 
(68/365). The proportions of women with low avidity HPV16 antibodies who were 
also HPV6/11, HPV31/33 or HPV18/45 positive were 33.8%, 10.8% and 14.3% 
respectively (Table 9). After stratification by country, the proportion of low-avidity 
HPV16 antibodies was significantly lower among Finnish (15%) than Ugandan 
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(26%) women (p<0.0001). The age-, C. trachomatis seropositivity and smoking-
adjusted risk for being seropositive to lrHPVtypes 6/11 among women with low-
avidity HPV16 antibodies was significantly increased among Ugandan women (OR 
2.21, 95%CI 1.01-8.40) compared to Finnish women (OR 0.80, 95%CI 0.94-6.82) 
(Table 9).  
 
Table 9. Association (adjusted odds ratio, OR, with 95% confidence interval, CI) of low 
avidity HPV16 antibodies with increased risk of being seropositive for other HPV 
types among Finnish and Ugandan women.  
 
Population 
 
Seropositivity 
 
Total 
Number 
with low 
Ab-avidity 
 
OR1 (95% CI) 
 
OR2 (95% CI) 
 
OR3 (95% CI) 
Finland (n=248) HPV16 only 113 19 1 1 1 
 HPV16+6 or 11 36 8 1.1 (0.4-2.8) 1.9 (0.6-6.1) 0.8 (0.1-6.8) 
 HPV16+31 or 33 59 5 0.3 (0.1-1.0) 0.3 (0.1-1.3) 0.8 (0.0-1.0) 
 HPV16+18 or 45 40 6 0.7 (0.2-1.8) 0.5 (0.1-2.0) 0.3 (0.2-3.8 ) 
       
Uganda (n=117) HPV16 only 45 9 1 1 1 
 HPV16+6 or 11 32 15 3.5 (1.3-9.7) 3.0 (1.1-8.5) 2.9 (1.0*-8.4) 
 HPV16+31 or 33 24 4 0.8 (0.2-2.9) 0.7 (0.2-2.5) 0.6 (0.2-2.3) 
 HPV16+18 or 45 16 2 0.6 (0.1-3.0) 0.5 (0.1-2.9) 0.5 (1.0-2.8) 
Cutoff-30% = using low-avidity controls mean plus 3 standard deviations 
OR1=adjusted for age; OR2=adjusted for age, Chlamydia trachomatis, HIV  
OR3=adjusted for age, C. trachomatis, HIV and smoking; *1.0  = lower 95% confidence limit 1.01 
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6 DISCUSSION 
 
 
HPV is the most common sexually transmitted infectious agent with a high trans-
mission probability of about 0.6 per act and a lifetime expectance for acquisition of 
80%. Fortunately, HPVinfection is transient in 90% of immunocompetent women 
(Kjellberg et al. 1999, Ho et al. 2004, Barnabas et al. 2006, Syrjanen et al. 2009). 
HPV prevalence is age-dependent, peaking after sexual debut below 25 years of age, 
thereafter leveling out and decreasing slightly for the next 35 to 40 years (Kjaer et al. 
2001, Viscidi et al 2004, Leinonen et al. 2008, Bosch et al. 2008, Syrjanen et al. 
2009 ). A second peak at about 45 years of age has been reported in some regions 
(Castellsaque et al. 2009, Munoz et al. 2009, Bruli et al. 2010).  
 
In the developing countries HPV types 51, 52, and 58 have been reported to be the 
most common followed by HPV16 among women with normal cytology (Clifford et 
al. 2005, Bruni et al. 2010, Banura et al. 2011). In the developed countries the most 
common types are HPV16, 18, 45, 31 (de Sanjose et al. 2007, Smith et al. 2008, 
Bruni et al. 2010).  In the ICC, however, the most common HPV types in all regions 
are HPV16, 18, 45, 31, 33, 52, 58, and 35 (de Sanjose et al. 2010, Li et al. 2011). 
Among HIV positive ICC cases the commonest types are HPV16, HPV18 and 
HPV45 (Clifford et al. 2006, Odida et al. 2011).  
 
Multiple HPV infections have been reported more in young sexually active women 
and among HIV-positive individuals, and are heavily dependent on HPV acquisition 
and persistence rates (Banura et al. 2010, 2011, Luovanto et al. 2010). Notable pro-
portions of ICC cases are also positive for more than one HPV type (Mejlhede et al. 
2009, Li et al. 2010, Pista et al. 2010, Odida et al. 2011). HPV serology identifies 
both current and past infections with approximately equal sensitivity. Thus, single 
and/or multiple HPV infections can be studied assessing trends of HPV infections in 
unvaccinated populations.  
 
The present seroepidemiological study on the occurrence of multiple type HPV in-
fections compares HPV epidemiology in Finland and Uganda. The choice of HPV 
types (lrHPV 6, 11 and hrHPV 16, 18, 31, 33, 35, 45, 51, 58) in our study is based 
on the protective effect documented from the current HPV vaccines (Brown et al. 
2009, Wheeler et al. 2009, 2011), and also reflects their dominant role in HPV-
associated disease burden in the two countries and large also in regions of the world.  
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6.1 Study strengths and limitations 
 
Representativeness of the study populations and sub-samples 
 
The women enrolled in our study were pregnant, which represent sexually active 
women with mean ages of 22 and 23 years for Finnish and Ugandan women respec-
tively. These cohorts are similar to those of other studies reporting a multiple HPV 
DNA prevalence peak in <30 year-old women (Clifford et al. 2004, Smith et al. 
2008, Nielsen et al. 2008, Luovanto et al. 2011). Cohorts of pregnant women have 
been used to report sexually transmitted infections (such as HIV, syphilis, hepatitis 
B, etc) in sexually active populations (Koskela et al. 2000, Lehtinen et al. 2006, 
Mpairwe et al. 2005), and probably represent women with normal distribution of 
cytological findings (Sarkola et al. 2009). Also, the slightly increased HPV DNA 
prevalence observed during pregnancy due to associated immune suppression is 
counterbalanced by the high rate of HPV clearance after delivery (Banura et al. 2008, 
Sarkola et al. 2009).  
 
Our large sample sizes allowed comparison of variables with ample (>80%) power 
and standard (5%) significance level for the identification of odds ratios of < 0.44 
and >1.82 for independent variables. Even if our study population was young, we 
expect to have covered all the types which matter in vaccination strategies given the 
currently available HPV vaccines. The geographical locations of the study popula-
tions made it possible to assess HPV epidemiology for HPV vaccinology for both 
developed and developing countries. 
 
In spite of moderate sensitivity of 50 to 70% the laboratory methods applied repre-
sented the most recent techniques, and the sensitivity reflects the fact of antibody 
response not existing in a number of HPV DNA positive/transiently infected indi-
viduals. The specificity of the serological methods was considered high (>98%) and 
they have been reported to be type-specific (Dillner et al. 1996, Waterboer et al. 
2005). This gave us an opportunity to study HPV type distributions and cumulative 
incidences of both single and multiple HPV types in young populations. Caution is 
warrented when comparing serological studies using different methods. A standard 
protocol for HPV serology studies is required for comparability of results from dif-
ferent regions. Lack of comparability may be one of the reasons for geographical 
differences in HPV seroepidemiological studies.  
 
 
On the other hand, the cross-sectional nature of our two studies (Papers I-II) made it 
impossible to define the order of acquiring infections with different HPV types. In 
the prospective study (Paper III) we assessed the order but the exact time from HPV 
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acquisition and sample collection was still not known. We also lacked HPV DNA 
and IgM data to estimate current HPV infections, and CD4 counts were also not 
available to assess the immunological competence of the HIV participants. 
 
6.2 Seroprevalence and HPV type distribution 
We demonstrated that seropositivity to any of the HPV types 6/11/16/18/31/33/45 
and multiple HPV types were common among both Finnish and Ugandan women 
(Paper I) similarly to previous studies (Laukkanen et al. 2003, Lehtinen et al. 2006, 
Kaasila et al. 2009). The prevalence peak in women under 25 years of age in our 
study is in line with earlier HPV DNA and seroepidemiology studies (Carter et al. 
2000, Lehtinen et al. 2006, Syrjanen et al. 2009, Porras et al. 2010). The high preva-
lence of HPV among young age groups has been suggested to be a result of in-
creased risky taking sexual behaviour among young people worldwide. In Finland, 
seroprevalence to specific HPV types is on the increase among young women 
(Laukkanen et al. 2003, Lehtinen et al. 2006, Kaasila et al. 2009, Syrjanen et al. 
2009, Merikukka et al. 2011). In Uganda, Botswana, Kenya and South Africa simi-
lar observations have been reported from both HPV DNA and/or serology studies 
(De Vuyst et al. 2010, Banura et al. 2011, Firnhaber et al. 2011, Marais et al. 2008).  
 
In our study the seroprevalence for multiple HPV types was lower among Finnish 
women than  Ugandan women. This may have been due to the prevalence of HIV 
infection among the Ugandan women, which was 7%, compared to zero among the 
Finnish women. HIV is associated with increased HPV acquisition/persistence (Clif-
ford et al. 2005, Marais et al. 2008, Banura et al. 2010, 2011) hence increased multi-
ple HPV prevalence. This has also been reflected in geographical differences re-
ported from the meta-analyses of HPV DNA studies in young women. The highest 
prevalences of both single and multiple HPV infections were reported in African 
countries (Clifford et al. 2004, de Sanjose et al. 2008, Smith et al. 2008, Bruni et al. 
2010). Within Africa, the prevalences were highest in East Africa (including Uganda) 
where HIV is endemic. In Ugandan women the multiple HPV prevalence was higher 
among HIV positive HIV negative women in line with other studies (Viscidi et al. 
2004, Mbulawa et al. 2010, Banura et al. 2011). 
 
The mean ages at sexual debut for both groups are very similar: 16.2 years among 
Ugandan women (Slaymaker et al. 2009) and 16.6 years among Finnish women 
(Haavo-Mannila et al. 2001). Ugandan women may engage in risky sexual activities 
which expose them to high-risk partners at a younger age than do Finnish women. 
Also, more common unprotected sex among Ugandan women might explain the 
increase in multiple infection rates (Neema et al. 2004). In our second study (Paper 
II), however, there was no significant association between seropositivity to multiple 
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hrHPV and age at sexual debut. This concurs with earlier studies suggesting that 
young age at sexual debut, although a risk factor for HPV DNA positivity, is not a 
stand-alone risk factor for HPV seropositivity but increases the frequency of HPV 
exposure among young people (Aral et al. 1999, 2008, Kahn et al. 2002, Collins et al. 
2002). This, in turn, could lead to seroconversion (Carter et al. 2000, Ho et al. 2002, 
Syrjanen et al. 2009, Porras et al. 2010). 
 
Among the Ugandan women, risk factors of seropositivity for multiple hrHPV types 
were young age (<30 years), low levels of education (< secondary level), parity (> 5) 
and HIV positivity, while number of lifetime sexual partners, age at debut, smoking 
had no effect (Paper II). This suggests that young women in Uganda face the risk of 
HPV acquisition(s) due to cross-age generation marriages/relationships, and po-
lygamous marriages as reported previously (Uganda Bureau of Statistics. 2001, 
Munoz et al. 2002, Wellings et al. 2006, Munoz et al. 2009) or coerced sex (Neema 
et al. 2004), which increase their risk of acquiring of multiple HPV infections from 
the risk-taking sexual network of their partners compared to the Finnish women with 
multiple partners (Auvinen et al. 2005, Louvanto et al. 2011).  
 
The HPV seropositivity rates among Finnish women may have been affected by 
smoking, which is more prevalent in Finnish (26%) than in Ugandan (3%) women. 
Smoking is associated with impaired antibody response in natural HPV infections 
(Simen-Kapeu et al. 2008, Syrjanen et al. 2009). Highly prevalent C. trachomatis 
seropositivity (26%) was not associated with seropositivity for multiple HPV types, 
although it is a proxy for increased risky taking sexual behaviour (Samoff et al. 
2005), and has been associated with HPV DNA positivity (Luovanto et al. 2011).  
 
6.3 Risk of co-occurrence of HPV types  
 
Our results showed that if a woman was seropositive for any of the specific HPV 
types (6/11/16/18/31/33/45), her risk estimate of being seropositive for another HPV 
type was significantly increased compared to a seronegative woman for that particu-
lar type. Our results agree with previous work that showed HPV seropositivity as a 
risk factor for multiple HPV types (Carter et al. 2000, Lehtinen et al. 2006, Kaasila 
et al. 2009). The reasons why HPV antibodies induced in natural HPV infections are 
not cross-protective are still unclear but there is speculation that the antibody titres 
are not high enough (Stanley et al. 2010, Safaeian et al. 2010, Paaso et al. 2011). 
The slow process of seroconversion may also contribute at young ages and high 
incidence peaks. Possibly the HPV viral load among sexually active women is 
higher than what cross-reactive antibodies could neutralize (Viscidi et al. 1997, 
Wang & Hildesheim 2001). Some follow-up studies have suggested that higher HPV 
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antibody levels are protective against incident infections of both related and unre-
lated type (Ho et al. 2002, Malik et al. 2009, Paaso et al. 2011).  
 
We further observed that Finnish women had a significantly increased risk of double 
seropositivity involving HPV18 and 45 compared to Ugandan women. HPV45 and 
HPV18 are responsible for adenocarcinoma diseases. The observed increased risk 
among Finnish women could be an effect of long time screening that may have 
changed the HPV ecological niche in Finland to favour the alpha 7 HPV species 
because adenocarcinoma and pre-adenocarcinomatous lesions, which are poorly 
detected by current techniques, have been on the increase in countries with orga-
nized cytology screening programmes (Bray et al. 2005, Bulk et al. 2005, Pettersson 
et al. 2011). In Finland, a possible competitive advantage has been associated with 
HPV type 33 but not HPV18 or HPV45 (Merikukka et al. 2011). Our observation 
needs to be investigated further in order to predict how the prevalance reduction or 
elimination of HPV6/11/16/18 included in the current vaccines following mass HPV 
vaccination will affect the occurrence of other genital HPV types.  
 
HPV 33 was the most common type among Ugandan women and in Ugandan ICC 
cases, and has previously been detected at a rate of 87.5% in multiple HPV infec-
tions. Its interaction with other HPV types, however, is not well understood. HPV16 
as a single infection or in combination with other types increases the risk of CIN and 
CC development (de Sanjose et al. 2010). The increased risk of multiple seropositiv-
ity for oncogenic types (both vaccine and non-vaccine related) among HPV16 and 
HPV33 seropositives should be monitored.   
 
Compared to East Africa HPV16 has been more common in Europe (De Vuyst et al. 
2009, Bruni et al. 2010, Banura et al. 2011) probably because the European 
HPV16/18 strains persist longer than African strains. In East Africa HPV52 is most 
common in cytologically normal populations (Banura et al. 2011), however, 
HPV16/18 predominate in cervical tissue samples (de Vuyst et al. 2011, Odida et al. 
2011) obtained from women with cytological abnormality due to persistent HPV 
infections.  
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6.4 Risk factors for seropositivity to multiple hrHPV types  
 
We observed young age, low education level, parity, HIV and C. trachomatis anti-
body positivity to be risk factors for seropositivity for multiple HPV types. This has 
been observed earlier in HPV DNA studies and serological studies. Our further 
analysis, however, indicated that HIV was the only independent, stand-alone risk 
factor.  
 
Multiple HPV infections have been reported in earlier studies to be more frequent 
among HIV positives than HIV negatives (Study I, Viscid et al. 2004, Clifford et al. 
2006, Banura et al. 2011). HIV has also been reported to be a stand-alone risk factor 
for multiple HPV infection (Banura et al. 2008). This is in line with with our results 
that HIV was the only independent, stand-alone risk for antibody positivity to multi-
ple HPV types. HIV is associated with HPV persistence and poor clearance of the 
virus (Banura et al. 2010) probably due to reduced levels of CD4 cells. On the other 
hand, the persistence of HPV has been reported to increase the risk of seroconver-
sion (Carter et al. 2000, Viscidi et al. 2004, Syrjanen et al. 2009). Furthermore, 
Uganda is one of the countries with the youngest population 
(http://www.africomnet.org/communication-resources/highlights/1182-uganda-has-
worlds-youngest-population.html) and highest frequencies of teenage pregnancies. 
This suggests that risky taking sexual behaviour, and also unprotected sex (preg-
nancy) exposes young women to other STIs such as HIV and C. trachomatis, which 
were risk factors for seropositivity to multiple HPV types in our study. These factors 
have previously been reported to increase the risk of multiple HPV acquistion and 
persistence (Banura et al. 2010).  
 
6.5 Risk of seroconversion for multiple HPV types in a longi-
tudinal study  
The results of our prospective follow up study indicated that women who at baseline 
were HPV seropositive for any of the HPV types 6/11/16/18/31/33/45 had an in-
creased risk of seroconverting to another HPV type. Seropositivity to any of the 
above mentioned HPV types increased the estimated risk for being seropositive for 
another type. This fits the observations that natural HPV-infection derived antibod-
ies do not protect against incident HPV infections (Viscidi et al. 2004). This has 
been suggested to be due to the low levels of antibodies induced in natural HPV 
infections compared the antibodies induced by the HPV vaccines which are logs 
higher than antibodies induced in natural infections (Olsson et al. 2008, Petäjä at al. 
2009). Antibodies induced by HPV vaccine are readily transduced to the mucosa to 
offer protection (Petaja et al. 2010).  Some studies, however, have suggested that 
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even if antibodies induced in natural HPV infections do not prevent new infections, 
they protect against disease (Carter et al. 2000). This was observed in the follow-up 
study, which showed that women who failed to seroconvert were at increased risk of 
precancerous lesions compared to seroconverted women (Carter et al. 2000, Viscidi 
et al. 2005, Syrjanen et al. 2009). On the other hand, a study by Ho et al. (2002) 
suggested that sustained high levels of antibodies to HPV16 were 50% protective 
against subsequent challenge by related types. A recent study in Finland has also 
suggested that former antibodies may protect against incident HPV infections with 
the same type (Paaso et al. 2011), but the level of antibodies that may offer protec-
tion is not known.  
 
The risk of seroconversion was observed for the alpha 9 phylogenetically related 
types 31 and 33 among women seropositive for either HPV16 or HPV 18. This has 
also been observed in a recent study by Merikukka et al. (2011) which showed a 
consistent excess risk of seroconversion for HPV33 among the baseline HPV16- and 
HPV18-seropositive women irrespective of age or presence or absence of antibodies 
to other HPV types. In our study, seropositivity for HPV31 or 33 was more common 
in individuals positive for HPV16, 18 and 45 antibodies (Papers I and II). Infections 
with HPV31 or HPV33 have been reported to persist for a long time (> 46 months), 
which may predispose to the suggested co-occurrence of HPV infections (Luovanto 
et al. 2010). These non-vaccine types need to be monitored because the cross-
protection to HPV31, 33 and 45 from the licenced HPV vaccines as reported in the 
earlier studies (Brown et al. 2009, Wheeler et al. 2009, 2011) may not last long.  
 
Seropositivity to multiple lrHPV types 6/11 at baseline increased the risk of sero-
conversion to multiple hrHPV types 16/18/31/33/45 but the reverse was not true. 
This may be explained by observations where seroconversion following infections 
with lrHPV types was faster than that following hrHPV infection. Moreover, lrHPV 
type antibodies were detectable for a shorter time than the hrHPV types antibodies 
(Carter et al. 2000). Seropositivity for multiple HPV types is also strongly associated  
with HPV16 seropositivity (Carter et al. 2000, Porras et al. 2010). HPV16 has been 
found in 50% - 87.5% of multiple HPV infections (de Ona et al. 2010, Luovanto et 
al. 2010). Both HPV16 and multiple hrHPV infections clear very slowly (Banura et 
al. 2010, Luovanto et al. 2010), which allows more time for seroconversion than in 
infections with lrHPV types. Carter et al (1996) showed that persistence of HPV16 
DNA was associated with seroconversion and SIL development among young 
women. 
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6.6 Low-avidity HPV16 antibodies associated with seroposi-
tivity for multiple lrHPV types 6/11 but not multiple 
hrHPV16/18/31/33/45.  
 
Low-avidity HPV16 antibodies were found in 15% of Finnish and 26% of Ugandan 
HPV16 seropositive women, and was associated with an increased risk of being 
seropositive for HPV6/11 but not for the hrHPV types 18/31/33/45. The risk was 
significantly increased among (non-smoking) Ugandan women but was probably 
confounded by smoking among Finnish women. 
 
Low antibody avidity indicates the immaturity of B-cells; therefore, it is widely 
recognized as a marker for acute infections (Hedman et al. 1989). The maturation of 
B cells depends on T-helper cell function (Stavnezer J. 1996, O’Rourke et al. 1997). 
In our study, the low avidity of HPV16 antibodies may therefore be due to recent 
HPV16 infection, genetic factors or immune suppression. Firstly, lrHPV6/11 anti-
bodies are detectable almost simultaneously with HPV6/11 DNA, whereas the ap-
pearance of antibodies to the high-risk HPV types takes a longer time. Sexual risky 
taking behaviour may have predisposed the study subjects (pregnant women) to a 
number of different low-risk and high-risk HPV types at about the same time but the 
antibody production is slower for hrHPV types.  
 
 
The association between low-avidity HPV16 antibodies and susceptibility to HPV 
types 6/11 was more obvious among Ugandan women compared to Finnish women. 
This may indicate an acute HPV16 infection among Ugandan pregnant women but 
IgM/DNA data to confirm this is lacking. Among the Ugandan women the HIV 
proportion was 9% (Paper IV) but had no effect on the HPV16 antibody avidity after 
stratifying by HIV status among Ugandan women. This was in line with earlier stud-
ies, which have demonstrated that antibody avidity in general is not affected by HIV 
infections (Bodeus et al. 1998, Lazzarotto et al. 1998).  One reason why the possible 
effect of HIV status on avidity of HPV16 antibodies was not seen in our study could 
be low number of cases, further studies with large numbers of subjects need to be 
considered. In contrast to natural infections, vaccination of immuno-suppressed 
individuals shows very slow maturations of antibody avidity compared to immuno-
competent individuals (Brinkman et al. 2003, Nair et al. 2009). This is because avid-
ity maturation is T-cell dependent, and the destruction of the activated helper T-cells 
by HIV, delays the maturation process in the germinal centres of the secondary lym-
phoid tissue. However, low antibody avidity may sometimes persist for a longer 
time after primary infections (Bodeus et al. 1998, Lazzarotto et al. 1998) probably 
due to the genetic factors of individuals. 
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On the other hand, smoking, which is strongly associated with impaired HPV-
antibody production (Simen-Kapeu et al. 2008), possibly also had an effect on HPV-
antibody avidity as the observed association (Paper IV) disappeared after adjusting 
for smoking among Finnish women. 
 
Women who are HPV16 seropositive at baseline have an increased risk estimate of 
seroconversion for other hrHPV types (Kaasila et al. 2009, Paper III). We found no 
association between low-avidity HPV16 antibodies and seropositivity for other 
hrHPV types, i.e., susceptibility to acquiring either phylogenetically related or unre-
lated hrHPVs. Thus the increased risk estimates of having multiple hrHPV infec-
tions once seropositivite for HPV16, may not be explained by specific (neutralizing) 
antibody avidity or related immunological maturation of antibody producing cells. 
 
Longitudinal studies are needed to establish whether low-avidity HPV16 antibodies 
persist for a longer period, and whether or not this plays a role in susceptibility to 
multiple HPV infections and progression to malignancy.  
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7 CONCLUSION  
 
 
The current work was undertaken to study the occurrence of common HPV types 
among the Finnish and Uganda female populations and to determine the risk of 
occurrence of HPV antibodies to infections with multiple HPV types  
 
1. Antibodies to multiple HPV types were very common among both Finnish and 
Ugandan women, but were most common in Ugandan women. HPV seroposi-
tive women (positive for any of the HPV types 6/11/16/18/31/33/45) compared 
to seronegative women for that particular type had an increased risk of being 
seropositive for other HPV type. The most common hrHPV antibodies among 
Finnish women were against HPV16 and HPV18 and the least common were 
against HPV45, whereas among the Ugandan women HPV33, HPV16, and 
HPV31 antibodies were most common, and HPV18 antibodies least common.  
 
2. The risk factors of seropositivity for multiple HPV types among Ugandan 
women were; young age, low level of education, parity, and HIV positivity, but 
not the number of lifetime sexual partners. HIV positivity was the only inde-
pendent, stand-alone risk factor for seropositivity for multiple HPV types, but 
the relative risks of co-occurrence of antibodies to the hrHPV types were not 
significantly different in HIV-positive and HIV-negative women. 
 
3. HPV antibodies induced in natural HPV infections are not cross-protective 
against other HPV infections. On the contrary, the risk of seroconversion to an-
other HPV type was increased among seropositive women, who at baseline had 
antibodies to any HPV type. After stratification by HPV risk type, there was a 
statistically significant increased risk of seroconversion to hrHPV types among 
baseline lrHPV seropositive women compared to seronegative women. 
 
4. Among Ugandan women, the risk for being HPV6/11-antibody positive among 
women with low-avidity HPV16 antibodies was increased compared to those 
with high-avidity HPV16 antibodies. No comparable excess risk estimates were 
observed for hrHPV types. 
 
5. This was the first study to compare the risk of co-occurrence of HPV types 
between Finland and Uganda. It clearly shows that although the seropreva-
lences are higher among Ugandan women, probably due to HIV and other im-
munological and environmental factors, Finnish women too have high hrHPV 
seroprevalences. The reduction of CC incidence and mortality among Finnish 
women is probably due to population-based screening for cervical cancer in 
Finland, the means for which are lacking in Uganda. Mass HPV vaccination 
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will be most effective in the fight against cervical cancer by significantly reduc-
ing the causative agent (HPV) in a low developing country like Uganda. 
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